Compounds > adenine
Page last updated: 2024-10-16

adenine and Cancer of Liver

adenine has been researched along with Cancer of Liver in 159 studies

Research Excerpts

ExcerptRelevanceReference
"To compare the efficacies ofentecavir and adefovir in patients with chronic hepatitis B (CHB) and cirrhosis when administered as monotherapies using a 240-week course."9.20[A randomized controlled trial on 240-week monotherapy with entecavir or adefovir in patients with chronic hepatitis B and cirrhosis]. ( Gao, Y; Han, T; Lian, J; Liu, F; Lyu, H; Wang, F; Xiang, H, 2015)
"Treatment with adefovir dipivoxil for 48 weeks resulted in clinical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B that was lost when treatment was discontinued."9.12Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. ( Arterburn, S; Borroto-Esoda, K; Brosgart, CL; Chang, TT; Chuck, SL; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Ma, J; Marcellin, P; Rizzetto, M; Tassopoulos, NC, 2006)
" Lamivudine and adefovir dipivoxil are effective and tolerable for chronic hepatitis B by suppressing the viral load and to reduce fibrosis in the liver."8.87Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma. ( Li, le Q; Wu, LC; Zhong, JH, 2011)
"As an effective targeted therapy for advanced hepatocellular carcinoma (HCC), sorafenib resistance has been frequently reported in recent years, with the activation of autophagy by cancer cells under drug stress being one of the crucial reasons."8.023-Methyladenine-enhanced susceptibility to sorafenib in hepatocellular carcinoma cells by inhibiting autophagy. ( Feng, G; Guo, R; Liu, J; Su, Z; Zhai, Y; Zhang, H; Zhao, F; Zhu, J, 2021)
" This study aimed to compare the efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) in relation to the adverse clinical outcomes among chronic hepatitis B (CHB) patients stratified according to adherence to medication and MVR."8.02Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. ( Jeong, J; Jung, SW; Kim, MJ; Lee, SB; Park, BR; Park, EJ; Park, NH; Shin, JW, 2021)
"To compare the reduction of hepatocellular carcinoma (HCC) risk between long-term treatment of entecavir and low genetic barrier antiviral agents in hepatitis B virus (HBV)-related cirrhotic patients."7.91Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching. ( Li, T; Lin, C; Qu, Y; Wang, L; Wang, Y; Yang, B, 2019)
" He had been receiving adefovir dipivoxil (ADV) for the treatment of entecavir (ETV)-resistant chronic hepatitis B (CHB) for four years in his 8-year treatment of hepatocellular carcinoma (HCC), but was referred to our hospital after increased levels of bone pain in his ribs, knees, and ankles."7.91[Adefovir Dipivoxil-induced Fanconi's Syndrome and Osteomalacia Following Multiple Bone Fractures in a Patient with Chronic Hepatitis B]. ( Ikeda, A; Ikeda, F; Kanzaki, H; Kitamura, Y; Makita, T; Murakawa, K; Nishihara, S; Okada, H; Onishi, H; Sendo, T; Shiraha, H; Takaki, A; Takeuchi, Y; Tanaka, Y; Wada, N; Yasunaka, T, 2019)
"Adefovir-induced hypophosphatemic osteomalacia in the context of hepatocarcinoma is rare and needs to be differentiated from metastatic hepatocarcinoma."7.85Adefovir-Induced Hypophosphatemic Osteomalacia Mimicking Bone Metastases From Primary Hepatocarcinoma. ( Luo, QY; Qiu, ZL; Shen, CT; Sun, ZK; Wei, WJ, 2017)
" Here, we explored the impact of salvianolic acid B (Sal B), the major water-soluble compounds of Danshen, on apoptosis and autophagy of human hepatocellular carcinoma cells (HCC)."7.83AKT/mTOR signaling pathway is involved in salvianolic acid B-induced autophagy and apoptosis in hepatocellular carcinoma cells. ( Chen, G; Chen, P; Di, C; Gong, L; Shi, J; Wang, J; Xia, X; Xu, H; Zhang, W, 2016)
"The risk of hepatocellular carcinoma (HCC) in Caucasian patients with chronic hepatitis B (CHB), treated with entecavir (ETV) or tenofovir (TDF), is unclear."7.81Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. ( Arends, P; Buti, M; Colombo, M; Dalekos, GN; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HL; Keskın, O; Lampertico, P; Mangia, G; Manolakopoulos, S; Papaioannou, C; Papatheodoridis, GV; Savvidou, S; Sypsa, V; Yurdaydin, C, 2015)
"Lamivudine (LAM) plus adefovir (ADV) combination therapy has been accepted as one of the best treatments for LAM-resistant chronic hepatitis B (CHB)."7.79Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients. ( Choe, WH; Kim, JH; Ko, SY; Kwon, SY; Lee, CH, 2013)
"Data concerning the outcome of lamivudine-resistant (LAM-R) chronic hepatitis B (CHB) patients with compensated cirrhosis under adefovir (ADV) treatment are limited."7.75Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance. ( Buti, M; Elefsiniotis, I; Esteban, R; Jardi, R; Vezali, E, 2009)
"We determined the clinical outcome of hepatitis e antigen (HBeAg)-negative chronic hepatitis B patients treated with long-term nucleos(t)ide analog therapy starting with lamivudine."7.73Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. ( Dimakopoulos, K; Dimou, E; Hadziyannis, SJ; Kitis, G; Manesis, E; Manolakopoulos, S; Papatheodoridis, GV; Rapti, I; Tzourmakliotis, D, 2005)
" Occupational exposure to vinyl chloride causes liver angiosarcomas (ASL) and also increases the risk of several other cancers."7.69p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. ( Harris, CC; Hollstein, M; Kusters, I; Lehman, T; Marion, MJ; Martel-Planche, G; Montesano, R; Welsh, J, 1994)
"Current therapies for chronic hepatitis B virus (HBV) infection do not provide adequate long-term control of viral replication in the majority of patients."6.70Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. ( Brosgart, C; Delaney, WE; Fry, J; Gibbs, CS; Heathcote, EJ; Ho, V; Miller, MD; Westland, CE; Xiong, S; Yang, H, 2002)
"Stimulation of HBV-infected hepatoma cells with IL-1β to validate the antiviral activity of IL-1β."5.91The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy. ( Hu, X; Li, Y; Luo, H; Qin, B; Tan, G, 2023)
"Hirsutanol A has potent cytotoxic effect, and can induce autophagic cell death via increasing ROS production."5.36A novel sesquiterpene Hirsutanol A induces autophagical cell death in human hepatocellular carcinoma cells by increasing reactive oxygen species. ( Deng, R; Feng, GK; Gao, YH; Jiang, S; Li, DD; Li, HJ; Wei, ZX; Wu, KW; Wu, XQ; Yang, F; Zhu, XF, 2010)
"To compare the efficacies ofentecavir and adefovir in patients with chronic hepatitis B (CHB) and cirrhosis when administered as monotherapies using a 240-week course."5.20[A randomized controlled trial on 240-week monotherapy with entecavir or adefovir in patients with chronic hepatitis B and cirrhosis]. ( Gao, Y; Han, T; Lian, J; Liu, F; Lyu, H; Wang, F; Xiang, H, 2015)
"In patients with hepatitis B-related HCC, adefovir antiviral therapy reduced late HCC recurrence and significantly improved overall survival after R0 hepatic resection."5.20Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. ( Huang, G; Lau, WY; Pan, ZY; Shen, F; Wang, ZG; Wu, MC; Yuan, SX; Zhou, WP, 2015)
"Treatment with adefovir dipivoxil for 48 weeks resulted in clinical improvement in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B that was lost when treatment was discontinued."5.12Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. ( Arterburn, S; Borroto-Esoda, K; Brosgart, CL; Chang, TT; Chuck, SL; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Ma, J; Marcellin, P; Rizzetto, M; Tassopoulos, NC, 2006)
" Lamivudine and adefovir dipivoxil are effective and tolerable for chronic hepatitis B by suppressing the viral load and to reduce fibrosis in the liver."4.87Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma. ( Li, le Q; Wu, LC; Zhong, JH, 2011)
" Treatment options for chronic hepatitis B include pegylated interferon and 4 licensed oral nucleosides/nucleotides (lamivudine, adefovir entecavir and tenofovir)."4.84[Chronic hepatitis B: current therapy]. ( Buffet, C, 2008)
" This study aimed to compare the efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) in relation to the adverse clinical outcomes among chronic hepatitis B (CHB) patients stratified according to adherence to medication and MVR."4.02Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. ( Jeong, J; Jung, SW; Kim, MJ; Lee, SB; Park, BR; Park, EJ; Park, NH; Shin, JW, 2021)
"As an effective targeted therapy for advanced hepatocellular carcinoma (HCC), sorafenib resistance has been frequently reported in recent years, with the activation of autophagy by cancer cells under drug stress being one of the crucial reasons."4.023-Methyladenine-enhanced susceptibility to sorafenib in hepatocellular carcinoma cells by inhibiting autophagy. ( Feng, G; Guo, R; Liu, J; Su, Z; Zhai, Y; Zhang, H; Zhao, F; Zhu, J, 2021)
" MATERIAL AND METHODS SMMC-7721 cells (a hepatocellular carcinoma cell line) were treated with different concentrations of oleanolic acid (OA) plus autophagy inhibitor 3-methyladenine (3-MA) (3-MA+OA) or chloroquine (CQ) plus OA (CQ+OA)."3.96Effect of Oleanolic Acid on Apoptosis and Autophagy of SMMC-7721 Hepatoma Cells. ( Wu, X; Zeng, X; Zhou, W, 2020)
" He had been receiving adefovir dipivoxil (ADV) for the treatment of entecavir (ETV)-resistant chronic hepatitis B (CHB) for four years in his 8-year treatment of hepatocellular carcinoma (HCC), but was referred to our hospital after increased levels of bone pain in his ribs, knees, and ankles."3.91[Adefovir Dipivoxil-induced Fanconi's Syndrome and Osteomalacia Following Multiple Bone Fractures in a Patient with Chronic Hepatitis B]. ( Ikeda, A; Ikeda, F; Kanzaki, H; Kitamura, Y; Makita, T; Murakawa, K; Nishihara, S; Okada, H; Onishi, H; Sendo, T; Shiraha, H; Takaki, A; Takeuchi, Y; Tanaka, Y; Wada, N; Yasunaka, T, 2019)
"To compare the reduction of hepatocellular carcinoma (HCC) risk between long-term treatment of entecavir and low genetic barrier antiviral agents in hepatitis B virus (HBV)-related cirrhotic patients."3.91Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching. ( Li, T; Lin, C; Qu, Y; Wang, L; Wang, Y; Yang, B, 2019)
"Adefovir-induced hypophosphatemic osteomalacia in the context of hepatocarcinoma is rare and needs to be differentiated from metastatic hepatocarcinoma."3.85Adefovir-Induced Hypophosphatemic Osteomalacia Mimicking Bone Metastases From Primary Hepatocarcinoma. ( Luo, QY; Qiu, ZL; Shen, CT; Sun, ZK; Wei, WJ, 2017)
" Here, we explored the impact of salvianolic acid B (Sal B), the major water-soluble compounds of Danshen, on apoptosis and autophagy of human hepatocellular carcinoma cells (HCC)."3.83AKT/mTOR signaling pathway is involved in salvianolic acid B-induced autophagy and apoptosis in hepatocellular carcinoma cells. ( Chen, G; Chen, P; Di, C; Gong, L; Shi, J; Wang, J; Xia, X; Xu, H; Zhang, W, 2016)
"The risk of hepatocellular carcinoma (HCC) in Caucasian patients with chronic hepatitis B (CHB), treated with entecavir (ETV) or tenofovir (TDF), is unclear."3.81Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. ( Arends, P; Buti, M; Colombo, M; Dalekos, GN; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HL; Keskın, O; Lampertico, P; Mangia, G; Manolakopoulos, S; Papaioannou, C; Papatheodoridis, GV; Savvidou, S; Sypsa, V; Yurdaydin, C, 2015)
"Since the licensing of lamivudine in 1999, the treatment of chronic hepatitis B has been revolutionized by the introduction of oral nucleoside and nucleotide analogues (NAs), which act as inhibitors of the HBV polymerase."3.80Antiviral therapy of chronic hepatitis B. ( Berg, T; van Bömmel, F, 2014)
" The first choice of therapy in chronic hepatitis B infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy."3.80[Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline]. ( Gervain, J; Horváth, G; Hunyady, B; Lengyel, G; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I, 2014)
"Lamivudine (LAM) plus adefovir (ADV) combination therapy has been accepted as one of the best treatments for LAM-resistant chronic hepatitis B (CHB)."3.79Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients. ( Choe, WH; Kim, JH; Ko, SY; Kwon, SY; Lee, CH, 2013)
"Data concerning the outcome of lamivudine-resistant (LAM-R) chronic hepatitis B (CHB) patients with compensated cirrhosis under adefovir (ADV) treatment are limited."3.75Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance. ( Buti, M; Elefsiniotis, I; Esteban, R; Jardi, R; Vezali, E, 2009)
"The long-term efficacy of adefovir dipivoxil in combination with lamivudine to chronic hepatitis B virus (HBV) infection is still unclear."3.74Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil. ( Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H, 2008)
"We determined the clinical outcome of hepatitis e antigen (HBeAg)-negative chronic hepatitis B patients treated with long-term nucleos(t)ide analog therapy starting with lamivudine."3.73Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. ( Dimakopoulos, K; Dimou, E; Hadziyannis, SJ; Kitis, G; Manesis, E; Manolakopoulos, S; Papatheodoridis, GV; Rapti, I; Tzourmakliotis, D, 2005)
" Occupational exposure to vinyl chloride causes liver angiosarcomas (ASL) and also increases the risk of several other cancers."3.69p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. ( Harris, CC; Hollstein, M; Kusters, I; Lehman, T; Marion, MJ; Martel-Planche, G; Montesano, R; Welsh, J, 1994)
"The role of hepatocellular carcinoma (HCC) in HBV recurrence remains unclear."2.73Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. ( Brechot, C; Castaing, D; Dussaix, E; Fallot, G; Faria, LC; Ferrari, TC; Gigou, M; Guettier, C; Roche, B; Roque-Afonso, AM; Samuel, D; Sebagh, M, 2008)
"Current therapies for chronic hepatitis B virus (HBV) infection do not provide adequate long-term control of viral replication in the majority of patients."2.70Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. ( Brosgart, C; Delaney, WE; Fry, J; Gibbs, CS; Heathcote, EJ; Ho, V; Miller, MD; Westland, CE; Xiong, S; Yang, H, 2002)
" Long-term use of NUCs with maintained viral suppression results in a decrease in liver-related complications."2.52Monotherapy for hepatitis B infection: a review of treatment options. ( Demirhan, YE; Gultekin, G; Isal, B; Khodor, H; Ozaras, R; Unal, UK; Yetim, N, 2015)
"Although a rather benign course of chronic hepatitis B virus (HBV) infection during childhood has been described, 3-5% and 0."2.50Management of chronic hepatitis B in children: an unresolved issue. ( Cainelli, F; Comparcola, D; Della Corte, C; Nobili, V; Vento, S, 2014)
"Registered treatment for chronic hepatitis B currently consists of (pegylated) interferon, lamivudine and adefovir, while entecavir is expected to be licensed in the short term."2.43Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression? ( Buster, EH; Janssen, HL, 2006)
"To address the clinical management of chronic hepatitis B virus (HBV) infection."2.43Management of chronic hepatitis B virus infection: current perspectives for the nurse practitioner. ( Perrillo, R, 2006)
"Lamivudine appears to be a safe and effective antiviral agent, which may improve or stabilize liver disease in selected patients with advanced cirrhosis and active HBV replication."2.42Management of patients with decompensated HBV cirrhosis. ( Fontana, RJ, 2003)
"Stimulation of HBV-infected hepatoma cells with IL-1β to validate the antiviral activity of IL-1β."1.91The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy. ( Hu, X; Li, Y; Luo, H; Qin, B; Tan, G, 2023)
"Baseline HBV loads do not affect the prognosis of HCC patients receiving anti-PD-1 in combination with an antiangiogenic therapy, while PD-1 inhibitors do not aggravate HBV reactivation and hepatic impairment in patients simultaneously subjected to TAF prophylaxis."1.72Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis. ( Chen, J; Hu, X; Li, Q; Li, R; Yuan, G; Zang, M, 2022)
"The prediction of hepatocellular carcinoma (HCC) development during nucleotide/nucleoside analog (NA) therapy is clinically important in patients with chronic hepatitis B."1.56Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog. ( Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Okada, M; Osawa, L; Sekiguchi, S; Shimizu, T; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Watakabe, K; Yamashita, K; Yasui, Y, 2020)
"A total of 28 orthotopic mice with hepatocellular carcinoma were randomly divided into 4 groups to receive different drug interventions."1.56Combination of HSP90 and autophagy inhibitors promotes hepatocellular carcinoma apoptosis following incomplete thermal ablation. ( Bao, H; Chen, F; Violetta, L; Xie, H; Zheng, S, 2020)
"The growth inhibition and autophagy of liver cancer cells were detected using acridine orange fluorescence staining, flow cytometry and transmission electron microscopy."1.48The biological role of autophagy in regulating and controlling the proliferation of liver cancer cells induced by bufalin. ( Li, Q; Qin, J; Sheng, X; Zhu, P, 2018)
"Mortality and complications including hepatocellular carcinoma are associated primarily with cirrhosis and age, but not with HBeAg status or viral load probably because modern therapies considerably reduce viral replication in almost all patients."1.43Long-term follow-up of HBsAg-positive patients in Germany. ( Amani, A; Niederau, C; Thiel, A, 2016)
"However, the effect of AZD8055 on hepatocellular carcinoma (HCC) cells has not been studied."1.40AZD8055 induces cell death associated with autophagy and activation of AMPK in hepatocellular carcinoma. ( Chen, M; Chen, N; Hu, M; Huang, H; Li, M; Li, P; Miao, H; Zhao, R, 2014)
" NVP-BEZ235 is a novel, orally bioavailable dual PI3K/mTOR inhibitor that has exhibited promising activity against HCC in preclinical models."1.39Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy. ( Chang, Z; Guo, H; Guo, X; Jia, X; Jin, J; Luo, F; Shi, G; Song, Y, 2013)
"Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) is the most frequent and difficult-to-treat viral hepatitis worldwide."1.39Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis. ( Bonino, F; Brunetto, MR; Caputo, A; Coco, B; Espinos, B; Iannazzo, S; Latour, A; Rossetti, F, 2013)
"Liver cancer is a common human cancer with a high mortality rate and currently there is no effective chemoprevention or systematic treatment."1.39Prostaglandin E2 promotes liver cancer cell growth by the upregulation of FUSE-binding protein 1 expression. ( Bai, XM; Chen, M; Guo, Y; Leng, J; Ma, J; Shu, W; Wang, YH; Wang, YP; Xia, SK; Xu, Y; Zhang, H; Zhang, L; Zhang, M, 2013)
"Therefore, we compared chronic hepatitis B patients who received NA therapy to those who did not, using a propensity analysis."1.39Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. ( Andou, Y; Hisanaga, Y; Kanamori, A; Kiriyama, S; Kumada, T; Niinomi, T; Tada, T; Tanaka, J; Tanikawa, M; Toyoda, H; Yamamoto, K; Yasuda, S, 2013)
"The relative resistance of liver cancer cells to ionizing radiation (IR) and chemotherapeutic agents due to autophagic response limits the available treatment options for this type of cancer."1.37Sensitizing effect of 3-methyladenine on radiation-induced cytotoxicity in radio-resistant HepG2 cells in vitro and in tumor xenografts. ( Chiang, HC; Chou, FP; Kuo, WH; Liu, WS; Tseng, HC; Tyan, YS, 2011)
"Hirsutanol A has potent cytotoxic effect, and can induce autophagic cell death via increasing ROS production."1.36A novel sesquiterpene Hirsutanol A induces autophagical cell death in human hepatocellular carcinoma cells by increasing reactive oxygen species. ( Deng, R; Feng, GK; Gao, YH; Jiang, S; Li, DD; Li, HJ; Wei, ZX; Wu, KW; Wu, XQ; Yang, F; Zhu, XF, 2010)
"In conclusion, autophagy decreases hepatoma cells sensitization to chemotherapeutic agents by affecting their apoptotic potential."1.35Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells. ( Gao, L; Guo, X; Qu, Z; Shen, F; Song, J; Sun, K; Wei, L; Wu, M; Zhao, Q; Zhao, X, 2009)
"Hepatitis B e antigen (HBeAg) negative chronic hepatitis B (CHB) is frequently caused by a mutation (G1896A) in the hepatitis B virus (HBV) precore (PC) reading frame that creates a stop codon, causing premature termination of the PC protein."1.32Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. ( Bowden, S; Chen, RY; Colledge, D; Delaney, WE; Desmond, P; Edwards, R; Isom, H; Locarnini, SA; Shaw, T, 2003)
"Worldwide, hepatocellular carcinoma (HCC) is more prevalent in men than in women, suggesting that sex hormones and/or X-chromosome-linked genes may be involved in hepatocarcinogenesis."1.31Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. ( Chang, HC; Chen, CJ; Chen, PJ; Cheng, SW; Hsiao, TJ; Lee, SD; Liaw, YF; Lin, MW; Lin, SM; Liu, CJ; Yang, SY; Yu, MW, 2000)
"In contrast, colorectal cancers with codon 12 aspartic acid substitutions accounted for most of the distant hematogenous deposits (P < 0."1.29Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. ( Christensen, S; Finkelstein, SD; Sayegh, R; Swalsky, PA, 1993)
"Alanosine treatment results in the inhibition of cell division, DNA synthesis, RNA and protein synthesis (in this order), and a depletion of the cells of adenosine triphosphate."1.26Alanosine toxicity in Novikoff rat hepatoma cells due to inhibition of the conversion of inosine monophosphate to adenosine monophosphate. ( Graff, JC; Plagemann, PG, 1976)
"In the hepatoma cells, the enzyme activities were also compared to the cellular content and synthesis of RNA and DNA."1.26Nucleotidase activity in regenerating liver and in clonal strains of hepatoma and pituitary cells in culture. ( Gautvik, KM; Tjernshaugen, H, 1976)
"Zajdela ascitic hepatoma cells are shown to take up pyrimidine bases at much lower rates than obtained in slices from normal rat liver."1.25Uptake in vitro of nucleic acid precursors and nucleic acids by Zajdela ascitic hepatoma cells. ( Bhargava, PM; Bornecque, CA; Szafarz, D; Zajdela, F, 1975)

Research

Studies (159)

TimeframeStudies, this research(%)All Research%
pre-199033 (20.75)18.7374
1990's12 (7.55)18.2507
2000's23 (14.47)29.6817
2010's69 (43.40)24.3611
2020's22 (13.84)2.80

Authors

AuthorsStudies
Wang, S2
Xu, X2
Che, D1
Fan, R1
Gao, M3
Cao, Y2
Ge, C1
Feng, Y1
Li, J10
Xie, S1
Wang, C3
Dai, F1
Gao, L3
Wang, Y14
Cui, H1
Rong, W1
Ma, J3
Zhu, Q1
Jiang, B2
Zhang, L5
Li, C4
Zhuo, Z1
Chen, M3
Lim, J1
Choi, WM1
Shim, JH1
Lee, D1
Kim, KM1
Lim, YS2
Lee, HC1
Choi, J2
Hu, X2
Li, R2
Li, Q4
Zang, M1
Yuan, G1
Chen, J5
Sato, K1
Inoue, J1
Akahane, T1
Kobayashi, T1
Takai, S1
Nakamura, T1
Sato, T1
Kimura, O1
Ninomiya, M1
Iwata, T1
Sano, A1
Tsuruoka, M1
Onuki, M1
Sawahashi, S1
Niitsuma, H1
Masamune, A1
Luo, H1
Tan, G1
Li, Y6
Qin, B1
Leu, YS1
Chen, YJ1
Chen, CC2
Huang, HL1
Lin, CH1
Elkholy, KH1
Wani, NA1
Li, D4
Hu, P1
Barajas, JM1
Yu, L2
Zhang, X12
Jacob, ST1
Khan, WN1
Bai, XF1
Noonan, AM1
Ghoshal, K1
Kirino, S1
Tamaki, N1
Kaneko, S2
Kurosaki, M1
Inada, K1
Yamashita, K1
Osawa, L1
Hayakawa, Y1
Sekiguchi, S1
Watakabe, K1
Okada, M1
Wang, W5
Shimizu, T1
Higuchi, M1
Takaura, K1
Maeyashiki, C1
Yasui, Y1
Nakanishi, H1
Tsuchiya, K1
Itakura, J1
Takahashi, Y1
Izumi, N1
Okubo, S1
Ohta, T1
Shoyama, Y1
Uto, T1
Halim, AA1
Alsayed, B1
Embarak, S1
Yaseen, T1
Dabbous, S1
Fontaine, O1
Dueluzeau, R1
Raibaud, P1
Chabanet, C1
Popoff, MR1
Badoual, J1
Gabilan, JC1
Andremont, A1
Gómez, L1
Andrés, S1
Sánchez, J1
Alonso, JM1
Rey, J1
López, F1
Jiménez, A1
Yan, Z2
Zhou, L1
Zhao, Y4
Wang, J8
Huang, L2
Hu, K1
Liu, H5
Wang, H5
Guo, Z1
Song, Y2
Huang, H5
Yang, R1
Owen, TW1
Al-Kaysi, RO1
Bardeen, CJ1
Cheng, Q1
Wu, S1
Cheng, T1
Zhou, X1
Wang, B5
Zhang, Q4
Wu, X4
Yao, Y4
Ochiai, T1
Ishiguro, H2
Nakano, R2
Kubota, Y2
Hara, M2
Sunada, K1
Hashimoto, K1
Kajioka, J1
Fujishima, A1
Jiao, J3
Gai, QY3
Zang, YP2
Niu, LL2
Fu, YJ4
Wang, X7
Yao, LP2
Qin, QP1
Wang, ZY1
Liu, J7
Aleksic Sabo, V1
Knezevic, P1
Borges-Argáez, R1
Chan-Balan, R1
Cetina-Montejo, L1
Ayora-Talavera, G1
Sansores-Peraza, P1
Gómez-Carballo, J1
Cáceres-Farfán, M1
Jang, J1
Akin, D1
Bashir, R1
Yu, Z1
Zhu, J3
Jiang, H1
He, C2
Xiao, Z1
Xu, J2
Sun, Q1
Han, D1
Lei, H1
Zhao, K2
Zhu, L1
Li, X8
Fu, H2
Wilson, BK1
Step, DL1
Maxwell, CL1
Gifford, CA1
Richards, CJ1
Krehbiel, CR1
Warner, JM1
Doerr, AJ1
Erickson, GE1
Guretzky, JA1
Rasby, RJ1
Watson, AK1
Klopfenstein, TJ1
Sun, Y4
Liu, Z4
Pham, TD1
Lee, BK1
Yang, FC1
Wu, KH1
Lin, WP1
Hu, MK1
Lin, L3
Shao, J1
Sun, M1
Xu, G1
Xu, N1
Wang, R2
Liu, S2
He, H1
Dong, X3
Yang, M2
Yang, Q1
Duan, S1
Yu, Y2
Han, J2
Zhang, C3
Chen, L2
Yang, X1
Li, W3
Wang, T2
Campbell, DA1
Gao, K1
Zager, RA1
Johnson, ACM1
Guillem, A1
Keyser, J1
Singh, B1
Steubl, D1
Schneider, MP1
Meiselbach, H1
Nadal, J1
Schmid, MC1
Saritas, T1
Krane, V1
Sommerer, C1
Baid-Agrawal, S1
Voelkl, J1
Kotsis, F1
Köttgen, A1
Eckardt, KU1
Scherberich, JE1
Li, H4
Yao, L2
Sun, L3
Zhu, Z1
Naren, N1
Zhang, XX2
Gentile, GL1
Rupert, AS1
Carrasco, LI1
Garcia, EM1
Kumar, NG1
Walsh, SW1
Jefferson, KK1
Guest, RL1
Samé Guerra, D1
Wissler, M1
Grimm, J1
Silhavy, TJ1
Lee, JH2
Yoo, JS1
Kim, Y1
Kim, JS2
Lee, EJ1
Roe, JH1
Delorme, M1
Bouchard, PA1
Simon, M1
Simard, S1
Lellouche, F1
D'Urzo, KA1
Mok, F1
D'Urzo, AD1
Koneru, B1
Lopez, G1
Farooqi, A1
Conkrite, KL1
Nguyen, TH1
Macha, SJ1
Modi, A1
Rokita, JL1
Urias, E1
Hindle, A1
Davidson, H1
Mccoy, K1
Nance, J1
Yazdani, V1
Irwin, MS1
Yang, S1
Wheeler, DA1
Maris, JM1
Diskin, SJ1
Reynolds, CP1
Abhilash, L1
Kalliyil, A1
Sheeba, V1
Hartley, AM2
Meunier, B2
Pinotsis, N1
Maréchal, A2
Xu, JY1
Genko, N1
Haraux, F1
Rich, PR1
Kamalanathan, M1
Doyle, SM1
Xu, C1
Achberger, AM1
Wade, TL1
Schwehr, K1
Santschi, PH1
Sylvan, JB1
Quigg, A1
Leong, W1
Xu, W2
Gao, S1
Zhai, X1
Gilson, E1
Ye, J1
Lu, Y1
Yan, R1
Zhang, Y8
Hu, Z2
You, Q1
Cai, Q1
Yang, D1
Gu, S1
Dai, H1
Zhao, X4
Gui, C1
Gui, J1
Wu, PK1
Hong, SK1
Starenki, D1
Oshima, K1
Shao, H1
Gestwicki, JE1
Tsai, S1
Park, JI1
Zhao, R2
Gu, Z1
Dong, C2
Guo, G1
Li, L5
Barrett, HE1
Meester, EJ1
van Gaalen, K1
van der Heiden, K1
Krenning, BJ1
Beekman, FJ1
de Blois, E1
de Swart, J1
Verhagen, HJ1
Maina, T1
Nock, BA1
Norenberg, JP1
de Jong, M1
Gijsen, FJH1
Bernsen, MR1
Martínez-Milla, J1
Galán-Arriola, C1
Carnero, M1
Cobiella, J1
Pérez-Camargo, D1
Bautista-Hernández, V1
Rigol, M1
Solanes, N1
Villena-Gutierrez, R1
Lobo, M1
Mateo, J1
Vilchez-Tschischke, JP1
Salinas, B1
Cussó, L1
López, GJ1
Fuster, V1
Desco, M1
Sanchez-González, J1
Ibanez, B1
van den Berg, P1
Schweitzer, DH1
van Haard, PMM1
Geusens, PP1
van den Bergh, JP1
Zhu, X1
Huang, X2
Xu, H4
Yang, G3
Lin, Z1
Salem, HF1
Nafady, MM1
Kharshoum, RM1
Abd El-Ghafar, OA1
Farouk, HO1
Domiciano, D1
Nery, FC1
de Carvalho, PA1
Prudente, DO1
de Souza, LB1
Chalfun-Júnior, A1
Paiva, R1
Marchiori, PER1
Lu, M2
An, Z1
Jiang, J2
Du, S1
Zhou, H1
Cui, J1
Wu, W1
Liu, Y7
Song, J2
Lian, Q1
Uddin Ahmad, Z1
Gang, DD1
Konggidinata, MI1
Gallo, AA1
Zappi, ME1
Yang, TWW1
Johari, Y1
Burton, PR1
Earnest, A1
Shaw, K1
Hare, JL1
Brown, WA1
Kim, GA1
Han, S1
Choi, GH1
Gallo, A1
Cancelli, C1
Ceron, E1
Covino, M1
Capoluongo, E1
Pocino, K1
Ianiro, G1
Cammarota, G1
Gasbarrini, A1
Montalto, M1
Somasundar, Y1
Lu, IC1
Mills, MR1
Qian, LY1
Olivares, X1
Ryabov, AD1
Collins, TJ1
Zhao, L1
Doddipatla, S1
Thomas, AM1
Nikolayev, AA1
Galimova, GR1
Azyazov, VN1
Mebel, AM1
Kaiser, RI1
Guo, S1
Yang, P1
Yu, X2
Wu, Y3
Zhang, H3
Yu, B2
Han, B1
George, MW1
Moor, MB1
Bonny, O1
Langenberg, E1
Paik, H1
Smith, EH1
Nair, HP1
Hanke, I1
Ganschow, S1
Catalan, G1
Domingo, N1
Schlom, DG1
Assefa, MK1
Wu, G2
Hayton, TW1
Becker, B1
Enikeev, D1
Netsch, C1
Gross, AJ1
Laukhtina, E1
Glybochko, P1
Rapoport, L1
Herrmann, TRW1
Taratkin, M1
Dai, W1
Shi, J3
Carreno, J1
Kloner, RA1
Pickersgill, NA1
Vetter, JM1
Kim, EH1
Cope, SJ1
Du, K1
Venkatesh, R1
Giardina, JD1
Saad, NES1
Bhayani, SB1
Figenshau, RS1
Eriksson, J1
Landfeldt, E1
Ireland, S1
Jackson, C1
Wyatt, E1
Gaudig, M1
Stancill, JS1
Happ, JT1
Broniowska, KA1
Hogg, N1
Corbett, JA1
Tang, LF1
Bi, YL1
Fan, Y2
Sun, YB1
Wang, AL1
Xiao, BH1
Wang, LF1
Qiu, SW1
Guo, SW1
Wáng, YXJ1
Sun, J2
Chu, S1
Pan, Q1
Zheng, S3
Ma, L1
Wang, L4
Hu, T1
Wang, F3
Han, Z2
Yin, Z1
Ge, X1
Xie, K1
Lei, P1
Dias-Santagata, D1
Lennerz, JK1
Sadow, PM1
Frazier, RP1
Govinda Raju, S1
Henry, D1
Chung, T1
Kherani, J1
Rothenberg, SM1
Wirth, LJ1
Marti, CN1
Choi, NG1
Bae, SJ1
Ni, L1
Luo, X1
Dai, T1
Yang, Y4
Lee, R1
Fleischer, AS1
Wemhoff, AP1
Ford, CR1
Kleppinger, EL1
Helms, K1
Bush, AA1
Luna-Abanto, J1
García Ruiz, L1
Laura Martinez, J1
Álvarez Larraondo, M1
Villoslada Terrones, V1
Dukic, L1
Maric, N1
Simundic, AM1
Chogtu, B1
Ommurugan, B1
Thomson, SR1
Kalthur, SG1
Benidir, M1
El Massoudi, S1
El Ghadraoui, L1
Lazraq, A1
Benjelloun, M1
Errachidi, F1
Cassar, M1
Law, AD1
Chow, ES1
Giebultowicz, JM1
Kretzschmar, D1
Salonurmi, T1
Nabil, H1
Ronkainen, J1
Hyötyläinen, T1
Hautajärvi, H1
Savolainen, MJ1
Tolonen, A1
Orešič, M1
Känsäkoski, P1
Rysä, J1
Hakkola, J1
Hukkanen, J1
Zhu, N1
Du, Q2
Hao, P1
Cao, X1
Li, CX1
Zhao, S1
Luo, XM1
Feng, JX1
Gonzalez-Cotto, M1
Guo, L1
Karwan, M1
Sen, SK1
Barb, J1
Collado, CJ1
Elloumi, F1
Palmieri, EM1
Boelte, K1
Kolodgie, FD1
Finn, AV1
Biesecker, LG1
McVicar, DW1
Qu, F1
Deng, Z1
Xie, Y2
Tang, J3
Chen, Z2
Luo, W1
Xiong, D1
Zhao, D1
Fang, J1
Zhou, Z1
Niu, PP1
Song, B1
Xu, YM1
Zhang, Z3
Qiu, N1
Yin, J1
Zhang, J4
Guo, W1
Liu, M2
Liu, T2
Chen, D5
Luo, K1
He, Z2
Zheng, G1
Xu, F1
Sun, W1
Yin, F1
van Hest, JCM1
Du, L2
Shi, X1
Kang, S1
Duan, W2
Zhang, S3
Feng, J2
Qi, N1
Shen, G1
Ren, H1
Shang, Q1
Zhao, W2
Yang, Z4
Jiang, X2
Alame, M1
Cornillot, E1
Cacheux, V1
Tosato, G1
Four, M1
De Oliveira, L1
Gofflot, S1
Delvenne, P1
Turtoi, E1
Cabello-Aguilar, S1
Nishiyama, M1
Turtoi, A1
Costes-Martineau, V1
Colinge, J1
Guo, Q1
Quan, M2
Dong, J1
Bai, J2
Han, R1
Cai, Y1
Lv, YQ1
Chen, Q1
Lyu, HD1
Deng, L1
Zhou, D1
Xiao, X1
De Langhe, S1
Billadeau, DD1
Lou, Z1
Zhang, JS1
Xue, Z1
Shen, XD1
Gao, F1
Busuttil, RW1
Kupiec-Weglinski, JW1
Ji, H1
Otano, I1
Alvarez, M1
Minute, L1
Ochoa, MC1
Migueliz, I1
Molina, C1
Azpilikueta, A1
de Andrea, CE1
Etxeberria, I1
Sanmamed, MF1
Teijeira, Á1
Berraondo, P1
Melero, I1
Zhong, Z1
Xie, X1
Yu, Q1
Zhou, C1
Liu, C2
Liu, W1
Chen, W2
Yin, Y1
Li, CW1
Hsu, JL1
Zhou, Q1
Hu, B1
Fu, P1
Atyah, M1
Ma, Q2
Xu, Y3
Dong, Q1
Hung, MC1
Ren, N1
Huang, P1
Liao, R1
Chen, X3
Cao, Q2
Yuan, X1
Nie, W1
Yang, J2
Shao, B1
Ma, X1
Bi, Z1
Liang, X1
Tie, Y1
Mo, F1
Xie, D1
Wei, Y1
Wei, X2
Dokla, EME1
Fang, CS1
Chu, PC1
Chang, CS1
Abouzid, KAM1
Chen, CS2
Blaszczyk, R1
Brzezinska, J1
Dymek, B1
Stanczak, PS1
Mazurkiewicz, M1
Olczak, J1
Nowicka, J1
Dzwonek, K1
Zagozdzon, A1
Golab, J1
Golebiowski, A1
Xin, Z1
Himmelbauer, MK1
Jones, JH1
Enyedy, I1
Gilfillan, R1
Hesson, T1
King, K1
Marcotte, DJ1
Murugan, P1
Santoro, JC1
Gonzalez-Lopez de Turiso, F1
Pedron, J1
Boudot, C1
Brossas, JY1
Pinault, E1
Bourgeade-Delmas, S1
Sournia-Saquet, A1
Boutet-Robinet, E1
Destere, A1
Tronnet, A1
Bergé, J1
Bonduelle, C1
Deraeve, C1
Pratviel, G1
Stigliani, JL1
Paris, L1
Mazier, D1
Corvaisier, S1
Since, M1
Malzert-Fréon, A1
Wyllie, S1
Milne, R1
Fairlamb, AH1
Valentin, A1
Courtioux, B1
Verhaeghe, P1
Fang, X1
Gao, H1
Bi, W1
Tang, H1
Cui, Y1
Fan, H1
Yu, H1
Mathison, CJN1
Chianelli, D1
Rucker, PV1
Nelson, J1
Roland, J1
Huang, Z2
Xie, YF1
Epple, R1
Bursulaya, B1
Lee, C1
Gao, MY1
Shaffer, J1
Briones, S1
Sarkisova, Y1
Galkin, A1
Li, N1
Hua, S1
Kasibhatla, S1
Kinyamu-Akunda, J1
Kikkawa, R1
Molteni, V1
Tellew, JE1
Jin, X1
Pang, B1
Liu, Q2
Liu, X4
Huang, Y2
Josephine Fauci, A1
Ma, Y1
Soo Lee, M1
Yuan, W1
Gao, R1
Qi, H1
Zheng, W1
Yang, F4
Chua, H1
Wang, K1
Ou, Y1
Huang, M1
Zhu, Y1
Yu, J2
Tian, J1
Zhao, M1
Hu, J1
Yao, C1
Zhang, B3
Usawachintachit, M1
Tzou, DT1
Washington, SL1
Hu, W1
Chi, T1
Sorensen, MD1
Bailey, MR1
Hsi, RS1
Cunitz, BW1
Simon, J1
Wang, YN1
Dunmire, BL1
Paun, M1
Starr, F1
Lu, W1
Evan, AP1
Harper, JD1
Han, G1
Rodrigues, AE1
Fouladvand, F1
Falahi, E1
Asbaghi, O1
Abbasnezhad, A1
Anigboro, AA1
Avwioroko, OJ1
Cholu, CO1
Sonei, A1
Fazelipour, S1
Kanaani, L1
Jahromy, MH1
Jo, K1
Hong, KB1
Suh, HJ1
Park, JH1
Shin, E1
Park, E1
Kouakou-Kouamé, CA1
N'guessan, FK1
Montet, D1
Djè, MK1
Kim, GD1
González-Fernández, D1
Pons, EDC1
Rueda, D1
Sinisterra, OT1
Murillo, E1
Scott, ME1
Koski, KG1
Shete, PB1
Gonzales, R1
Ackerman, S1
Cattamanchi, A1
Handley, MA1
Li, XX1
Xiao, SZ1
Gu, FF1
He, WP1
Ni, YX1
Han, LZ1
Heffernan, JK1
Valgepea, K1
de Souza Pinto Lemgruber, R1
Casini, I1
Plan, M1
Tappel, R1
Simpson, SD1
Köpke, M1
Nielsen, LK1
Marcellin, E1
Cen, YK1
Lin, JG1
Wang, YL1
Wang, JY1
Liu, ZQ1
Zheng, YG1
Spirk, D1
Noll, S1
Burnier, M1
Rimoldi, S1
Noll, G1
Sudano, I1
Penzhorn, BL1
Oosthuizen, MC1
Kobos, LM1
Alqatani, S1
Ferreira, CR1
Aryal, UK1
Hedrick, V1
Sobreira, TJP1
Shannahan, JH1
Gale, P1
Singhroy, DN1
MacLean, E1
Kohli, M1
Lessem, E1
Branigan, D1
England, K1
Suleiman, K1
Drain, PK1
Ruhwald, M1
Schumacher, S1
Denkinger, CM1
Waning, B1
Van Gemert, W1
Pai, M1
Myers, RK1
Bonsu, JM1
Carey, ME1
Yerys, BE1
Mollen, CJ1
Curry, AE1
Douglas, TA1
Alinezhadbalalami, N1
Balani, N1
Schmelz, EM1
Davalos, RV1
Kamaldinov, T1
Erndt-Marino, J1
Levin, M1
Kaplan, DL1
Hahn, MS1
Heidarimoghadam, R1
Farmany, A1
Lee, JJ1
Kang, J1
Park, S1
Cho, JH1
Oh, S1
Park, DJ1
Perez-Maldonado, R1
Cho, JY1
Park, IH1
Kim, HB1
Song, M1
Mfarrej, B1
Jofra, T1
Morsiani, C1
Gagliani, N1
Fousteri, G1
Battaglia, M1
Giuliano, C1
Levinger, I1
Vogrin, S1
Neil, CJ1
Allen, JD1
Lv, Y1
Yuan, R1
Cai, B1
Bahrami, B1
Chowdhury, AH1
Yang, C2
Qiao, Q1
Liu, SF1
Zhang, WH1
Kolano, L1
Knappe, D1
Volke, D1
Sträter, N1
Hoffmann, R1
Coussens, M1
Calders, P1
Lapauw, B1
Celie, B1
Banica, T1
De Wandele, I1
Pacey, V1
Malfait, F1
Rombaut, L1
Vieira, D1
Angel, S1
Honjol, Y1
Gruenheid, S1
Gbureck, U1
Harvey, E1
Merle, G1
Seo, G1
Lee, G1
Kim, MJ2
Baek, SH1
Choi, M1
Ku, KB1
Lee, CS1
Jun, S1
Park, D1
Kim, HG1
Kim, SJ1
Lee, JO1
Kim, BT1
Park, EC1
Kim, SI1
Ende, M1
Kirkkala, T1
Loitzenbauer, M1
Talla, D1
Wildner, M1
Miletich, R1
Criado, A1
Lavela, P1
Tirado, JL1
Pérez-Vicente, C1
Kang, D1
Feng, D2
Fang, Z1
Wei, F1
De Clercq, E2
Pannecouque, C1
Zhan, P1
Guo, Y2
Shen, Y1
Wang, Q4
Kawazoe, Y1
Jena, P1
Sun, Z1
Li, Z3
Liang, H2
Ma, G1
Huo, X1
Church, JS1
Chace-Donahue, F1
Blum, JL1
Ratner, JR1
Zelikoff, JT1
Schwartzer, JJ1
Fiseha, T1
Tamir, Z1
Yao, W1
Wang, P2
Mi, K1
Cheng, J2
Gu, C1
Huang, J2
Sun, HB1
Xing, WQ1
Liu, XB1
Zheng, Y1
Yang, SJ1
Wang, ZF1
Liu, SL1
Ba, YF1
Zhang, RX1
Liu, BX1
Fan, CC1
Chen, PN1
Liang, GH1
Yu, YK1
Wang, HR1
Li, HM1
Li, ZX1
Lalani, SS1
Anasir, MI1
Poh, CL1
Khan, IT1
Nadeem, M1
Imran, M1
Khalique, A1
Raspini, B1
Porri, D1
De Giuseppe, R1
Chieppa, M1
Liso, M1
Cerbo, RM1
Civardi, E1
Garofoli, F1
Monti, MC1
Vacca, M1
De Angelis, M1
Cena, H1
Kong, D1
Han, X1
Zhou, Y3
Xue, H2
Zhang, W5
Ruan, Z1
Li, S3
Noer, PR1
Kjaer-Sorensen, K1
Juhl, AK1
Goldstein, A1
Ke, C1
Oxvig, C1
Duan, C1
Kong, F1
Lin, S1
Wang, Z3
Bhattacharya, R1
Mazumder, D1
Yan, X2
Ma, C1
Tang, Y1
Kong, X1
Lu, J1
Zhang, M2
Vital-Jacome, M1
Cazares-Granillo, M1
Carrillo-Reyes, J1
Buitron, G1
Jacob, SI1
Douair, I1
Maron, L1
Ménard, G1
Rusjan, P1
Sabioni, P1
Di Ciano, P1
Mansouri, E1
Boileau, I1
Laveillé, A1
Capet, M1
Duvauchelle, T1
Schwartz, JC1
Robert, P1
Le Foll, B1
Xia, Y1
Chen, S1
Luo, M1
Wu, J3
Cai, S1
He, Y2
Garbacz, P1
Misiak, M1
Jackowski, K1
Yuan, Q1
Sherrell, PC1
Bi, X1
Nutho, B1
Mahalapbutr, P1
Hengphasatporn, K1
Pattaranggoon, NC1
Simanon, N1
Shigeta, Y1
Hannongbua, S1
Rungrotmongkol, T1
Caffrey, PJ1
Kher, R1
Bian, K1
Delaney, S1
Xue, J1
Wu, P1
Xu, L2
Yuan, Y1
Luo, J1
Ye, S1
Ustriyana, P1
Wei, B1
Raee, E1
Hu, Y1
Wesdemiotis, C1
Sahai, N1
Kaur, A1
Nigam, K1
Srivastava, S1
Tyagi, A1
Dang, S1
Millar, JE1
Bartnikowski, N1
Passmore, MR1
Obonyo, NG1
Malfertheiner, MV1
von Bahr, V1
Redd, MA1
See Hoe, L1
Ki, KK1
Pedersen, S1
Boyle, AJ1
Baillie, JK1
Shekar, K1
Palpant, N1
Suen, JY1
Matthay, MA1
McAuley, DF1
Fraser, JF1
Settles, JA1
Gerety, GF1
Spaepen, E1
Suico, JG1
Child, CJ1
Oh, BL1
Lee, JS1
Lee, EY1
Lee, HY1
Yu, HG1
Leslie, I1
Boos, LA1
Larkin, J1
Pickering, L1
Lima, HK1
Vogel, K1
Hampel, D1
Wagner-Gillespie, M1
Fogleman, AD1
Ferraz, SL1
O'Connor, M1
Mazzucchelli, TG1
Kajiyama, H1
Suzuki, S1
Shimbo, A1
Utsumi, F1
Yoshikawa, N1
Kikkawa, F1
Javvaji, PK1
Dhali, A1
Francis, JR1
Kolte, AP1
Roy, SC1
Selvaraju, S1
Mech, A1
Sejian, V1
DeSilva, S1
Vaidya, SS1
Mao, C1
Akhatayeva, Z1
Cheng, H1
Zhang, G1
Jiang, F1
Meng, X1
Elnour, IE1
Lan, X1
Song, E1
Rohde, S1
Antonides, CFJ1
Muslem, R1
de Woestijne, PCV1
der Meulen, MHV1
Kraemer, US1
Dalinghaus, M1
Bogers, AJJC1
Pourmand, A1
Ghassemi, M1
Sumon, K1
Amini, SB1
Hood, C1
Sikka, N1
Duan, H1
Chen, WP1
Fan, M1
Wang, WP1
Tan, SJ1
Xin, S1
Wan, LJ1
Guo, YG1
Tanda, S1
Gingl, K1
Ličbinský, R1
Hegrová, J1
Goessler, W1
Li, ZL1
Zhou, YL1
Yan, W1
Luo, L1
Su, ZZ1
Fan, MZ1
Wang, SR1
Zhao, WG1
Xu, D1
Hassan, HM1
Jiang, Z1
Bachmann, KF1
Haenggi, M1
Jakob, SM1
Takala, J1
Gattinoni, L1
Berger, D1
Bentley, RF1
Vecchiarelli, E1
Banks, L1
Gonçalves, PEO1
Thomas, SG1
Goodman, JM1
Mather, K1
Boachie, R1
Anini, Y1
Panahi, S1
Anderson, GH1
Luhovyy, BL1
Nafie, MS1
Arafa, K1
Sedky, NK1
Alakhdar, AA1
Arafa, RK1
Fan, S1
Hu, H1
Liang, J2
Hu, BC1
Wen, Z1
Hu, D1
Liu, YY1
Chu, Q1
Wu, MC4
Lu, X1
Wang, D1
Hu, M2
Shen, H1
Yao, M1
Dahlgren, RA1
Vysloužil, J1
Kulich, P1
Zeman, T1
Vaculovič, T1
Tvrdoňová, M1
Mikuška, P1
Večeřa, Z1
Stráská, J1
Moravec, P1
Balcar, VJ1
Šerý, O1
Qiao, L1
Xiong, X2
Peng, X1
Zheng, J1
Duan, J1
Xiao, W1
Zhou, HY1
Sui, ZY1
Zhao, FL1
Sun, YN1
Wang, HY1
Han, BH1
Jintao, X1
Shasha, Y1
Jincai, W1
Chunyan, L1
Mengya, Y1
Yongli, S1
Rasoanirina, BNV1
Lassoued, MA1
Miladi, K1
Razafindrakoto, Z1
Chaâbane-Banaoues, R1
Ramanitrahasimbola, D1
Cornet, M1
Sfar, S1
Liang, C1
Xing, Q1
Yi, JL2
Zhang, YQ1
Li, CY1
Tang, SJ1
Gao, C3
Sun, X1
Peng, M1
Sun, XF1
Zhang, T1
Shi, JH1
Liao, CX1
Gao, WJ1
Sun, LL1
Gao, Y4
Cao, WH1
Lyu, J1
Yu, CQ1
Wang, SF1
Pang, ZC1
Cong, LM1
Dong, Z1
Wu, F2
Wu, XP1
Jiang, GH1
Wang, XJ1
Wang, BY1
Li, LM1
Pan, L1
Wan, SP1
Yi, HWL1
He, HJ1
Yong, ZP1
Shan, GL1
Weng, TT1
Yan, SQ1
Gao, GP1
Wei, C1
Tao, FB1
Shao, ZH1
Yao, T1
Dong, S1
Shi, S1
Feng, YL1
Zhang, YW1
Wang, SP1
Shi, AX1
Operario, D1
Zhang, ZH1
Zhu, XF2
Zaller, N1
Gao, P1
Sun, YH1
Zhang, HB1
Chen, F1
Xie, H1
Bao, H1
Violetta, L1
Hercun, J1
Koh, C1
Heller, T1
Zhou, W1
Zeng, X1
Shin, JW1
Jeong, J1
Jung, SW1
Lee, SB1
Park, BR1
Park, EJ1
Park, NH1
Fang, Q1
Chen, H1
Cao, K1
Shan, W1
Wen, Q1
Liu, JD1
Gao, GD1
Zhang, K1
Song, YW1
Li, HB1
Diao, W1
Yu, W1
Lian, B1
Feng, W1
Sun, T1
Qu, M1
Zhao, C1
Gao, Z1
Kong, W1
Yip, TC1
Wong, GL1
Zhao, F1
Feng, G1
Su, Z1
Guo, R1
Zhai, Y1
Fan, Z1
Liu, P2
Han, H2
Liu, R1
Shu, M1
Jin, W1
Liang, Y1
Lin, G1
Nie, R1
He, L2
Jiang, Y1
Ma, CL1
Qiao, S1
Li, YC1
Wang, XF1
Sun, RJ1
Qian, RK1
Song, SD1
Wei, WJ1
Sun, ZK1
Shen, CT1
Qiu, ZL1
Luo, QY1
Zhang, N1
Lyu, X1
Li, B1
Xiong, H1
Huang, G3
Zeng, Y1
Lian, J2
Ni, Z1
He, F1
Kong, Y1
Ma, H1
You, H1
Ou, X1
Jia, J1
Guo, XL2
Hu, F2
Fang, JM1
Zhu, ZΖ1
Wei, LΧ1
Xu, Q1
Bazaz, R1
Denning, DW1
Zhang, SD1
Fang, SH1
Sheng, X1
Zhu, P1
Qin, J1
Yin, X1
Sui, S1
Xia, Z1
Shen, J1
Peng, W1
Wen, T1
Li, T2
Qu, Y1
Lin, C1
Yang, B1
Makita, T1
Kanzaki, H1
Onishi, H1
Ikeda, A1
Takaki, A1
Wada, N1
Takeuchi, Y1
Yasunaka, T1
Ikeda, F1
Shiraha, H1
Tanaka, Y1
Nishihara, S1
Murakawa, K1
Kitamura, Y1
Okada, H1
Sendo, T1
Huang, B1
Ji, L1
Liang, B1
Tu, T1
Ye, X1
Song, P1
Fan, J1
Luan, J1
Ju, D1
Tada, T4
Toyoda, H4
Yasuda, S2
Miyake, N1
Kumada, T4
Kurisu, A1
Ohisa, M1
Akita, T1
Tanaka, J3
Marzano, A2
Marengo, A1
David, E1
Rizzetto, M3
Iannazzo, S1
Coco, B1
Brunetto, MR1
Rossetti, F1
Caputo, A1
Latour, A1
Espinos, B1
Bonino, F1
Chang, Z1
Shi, G1
Jin, J1
Guo, H2
Guo, X2
Luo, F1
Jia, X1
Singal, AK1
Salameh, H1
Kuo, YF1
Fontana, RJ2
Kou, X1
Jing, Y1
Deng, W1
Sun, K3
Ye, F1
Yu, G1
Fan, Q1
Zhao, Q2
Wei, L2
Wu, M2
Kim, JH1
Ko, SY1
Choe, WH1
Kwon, SY1
Lee, CH1
Li, P1
Li, M1
Miao, H1
Chen, N1
Calvaruso, V1
Craxì, A2
Triolo, M1
Della Corte, C2
Colombo, M3
Stepp, MW1
Folz, RJ1
Zelko, IN1
Strasser, SI1
Horváth, G1
Hunyady, B1
Gervain, J1
Lengyel, G1
Makara, M1
Pár, A1
Szalay, F1
Telegdy, L1
Tornai, I1
Xia, WF1
Ma, XP1
Li, XR1
Dong, H1
Nobili, V1
Comparcola, D1
Cainelli, F1
Vento, S1
van Bömmel, F1
Berg, T1
Lau, WY2
Wang, ZG1
Pan, ZY2
Yuan, SX1
Shen, F3
Zhou, WP2
Gao, Q1
Geng, L1
Jiang, L1
Shi, B1
Papatheodoridis, GV2
Dalekos, GN1
Yurdaydin, C1
Buti, M2
Goulis, J1
Arends, P1
Sypsa, V1
Manolakopoulos, S2
Mangia, G1
Gatselis, N1
Keskın, O1
Savvidou, S1
Hansen, BE1
Papaioannou, C1
Galanis, K1
Idilman, R1
Esteban, R2
Janssen, HL2
Lampertico, P2
Coffin, CS1
Rezaeeaval, M1
Pang, JX1
Alcantara, L1
Klein, P1
Burak, KW1
Myers, RP1
Li, G1
Feng, S1
Kim, DH1
Omary, RA1
Larson, AC1
Ozaras, R1
Khodor, H1
Yetim, N1
Unal, UK1
Demirhan, YE1
Gultekin, G1
Isal, B1
Niederau, C1
Amani, A1
Thiel, A1
Zhong, J1
Xiu, P1
Wei, H1
Xu, Z2
Liu, F2
Furusyo, N1
Shimizu, M1
Ogawa, E1
Murata, M1
Hayashi, J1
Han, T1
Xiang, H1
Lyu, H1
Tsai, HW1
Lin, YJ1
Wu, HC1
Chang, TT2
Wu, IC1
Cheng, PN1
Yen, CJ1
Chan, SH1
Huang, W1
Su, IJ1
Tsuji, K1
Hiraoka, A2
Liang, D1
Song, W1
Zhai, S1
Zhang, LH1
Ye, M2
Jia, YL1
Xu, M1
Dou, CW1
Liu, ZK1
Xue, YM1
Yao, BW1
Ding, LL1
Tu, KS1
Zheng, X1
Liu, QG1
Gong, L1
Di, C1
Xia, X1
Chen, G1
Chen, P1
Murata, K1
Asano, M1
Matsumoto, A1
Sugiyama, M1
Nishida, N1
Tanaka, E1
Inoue, T1
Sakamoto, M1
Enomoto, N1
Shirasaki, T1
Honda, M1
Gatanaga, H1
Oka, S1
Kawamura, YI1
Dohi, T1
Shuno, Y1
Yano, H1
Mizokami, M1
Gan, G1
Zhu, D1
Zhao, J2
Mi, J1
Yeh, PY1
Lu, YS1
Hsu, CH1
Chen, KF1
Lee, WC1
Feng, WC1
Kuo, ML1
Cheng, AL1
Chien, RN1
Liaw, YF2
Akuta, N2
Suzuki, F2
Kawamura, Y2
Yatsuji, H2
Sezaki, H2
Suzuki, Y2
Hosaka, T2
Kobayashi, M4
Arase, Y2
Ikeda, K2
Kumada, H2
Warner, N1
Locarnini, S1
Buffet, C1
Imaizumi, T1
Higaki, Y1
Sakamoto, T1
Horita, M1
Mizuta, T1
Eguchi, Y1
Yasutake, T1
Ozaki, I1
Yamamoto, K2
Onohara, S1
Kawazoe, S1
Shigematsu, H1
Koizumi, S1
Kudo, S1
Tanaka, K1
Elefsiniotis, I1
Jardi, R1
Vezali, E1
Qu, Z1
Robertson, S1
Allie-Reid, F1
Vanden Berghe, W1
Visser, K1
Binder, A1
Africander, D1
Vismer, M1
De Bosscher, K1
Hapgood, J1
Haegeman, G1
Louw, A1
Gao, YH1
Wu, KW1
Deng, R1
Li, DD1
Wei, ZX1
Jiang, S1
Wu, XQ1
Feng, GK1
Li, HJ1
Hirakawa, M1
Saitoh, S1
Liu, YL1
Yang, PM1
Shun, CT1
Wu, MS1
Weng, JR1
Marcellin, P2
Xie, BS1
Zhao, HC1
Yao, SK1
Zhuo, DX1
Jin, B1
Lv, DC1
Wu, CL1
Ma, DL1
Shu, XM1
Ai, ZL1
Carosi, G1
Alberti, A2
Cariti, G1
Filice, G1
Levrero, M1
Mazzotta, F1
Pastore, G1
Piccinino, F1
Prati, D1
Raimondo, G1
Sagnelli, E1
Toti, M1
Brunetto, M1
Bruno, R1
Di Marco, V1
Ferrari, C1
Gaeta, GB1
Pollicino, T1
Puoti, M1
Santantonio, T1
Smedile, A1
Tseng, HC1
Liu, WS1
Tyan, YS1
Chiang, HC1
Kuo, WH1
Chou, FP1
Ebinuma, H1
Saito, H1
Zhong, JH1
Li, le Q1
Wu, LC1
Sone, Y1
Fujimori, M1
Song, JR1
Zhang, SS1
Deng, WJ1
Zhao, QD1
Xie, XQ1
Song, YJ1
Wei, LX1
Xie, SQ1
Zhang, YH1
Wang, CJ1
Kiriyama, S1
Tanikawa, M1
Hisanaga, Y1
Kanamori, A1
Niinomi, T1
Andou, Y1
Pan, CQ1
Hu, KQ1
Tsai, N1
Fu, SY1
Shu, G1
Xie, B1
Ren, F1
Liu, DC1
Zhou, J2
Yuan, L1
Xia, SK1
Shu, W1
Wang, YH1
Bai, XM1
Wang, YP1
Leng, J1
Yang, H1
Westland, CE1
Delaney, WE2
Heathcote, EJ2
Ho, V1
Fry, J1
Brosgart, C1
Gibbs, CS1
Miller, MD1
Xiong, S1
Chen, RY1
Edwards, R1
Shaw, T1
Colledge, D1
Isom, H1
Bowden, S1
Desmond, P1
Locarnini, SA1
Fisher, DA1
Huffam, SE1
SARTORELLI, AC1
UPCHURCH, HF1
NIXON, JC1
ZBARSKY, SH2
MANDEL, P1
WINTZERITH, M1
BORKOWSKA, I1
MANDEL, L1
CLARK, JB1
GREENBAUM, AL1
MCLEAN, P1
REID, E1
WHITCUTT, JM1
ROTH, JS1
Sagir, A1
Avci, A1
Erhardt, A1
Lörke, J1
Heintges, T1
Häussinger, D1
Dimou, E1
Dimakopoulos, K1
Rapti, I1
Kitis, G2
Tzourmakliotis, D1
Manesis, E1
Hadziyannis, SJ2
Jacquard, AC1
Brunelle, MN1
Pichoud, C1
Durantel, D1
Carrouée-Durantel, S1
Trepo, C1
Zoulim, F1
Perrillo, R1
Buster, EH1
Tassopoulos, NC1
Lim, SG1
Goodman, Z1
Brosgart, CL1
Borroto-Esoda, K1
Arterburn, S1
Chuck, SL1
Takamura, M1
Ichida, T1
Ohkoshi, S1
Tsubata, S1
Osaki, A1
Aoyagi, T1
Nomoto, M1
Uehara, K1
Terada, H1
Aoyagi, Y1
Faria, LC1
Gigou, M1
Roque-Afonso, AM1
Sebagh, M1
Roche, B1
Fallot, G1
Ferrari, TC1
Guettier, C1
Dussaix, E1
Castaing, D1
Brechot, C1
Samuel, D1
Miller, JA1
Miller, EC1
Heijtink, RA1
Kruining, J1
de Wilde, GA1
Balzarini, J1
Schalm, SW1
Hollstein, M1
Marion, MJ1
Lehman, T1
Welsh, J1
Harris, CC1
Martel-Planche, G1
Kusters, I1
Montesano, R2
Finkelstein, SD1
Sayegh, R1
Christensen, S1
Swalsky, PA1
Malins, DC2
Polissar, NL1
Garner, MM1
Gunselman, SJ1
Bjersing, L1
Andersson, C1
Lithner, F1
Buckwold, VE1
Yen, TS1
Ou, JH1
Kitade, Y1
Nakanishi, M1
Hosoya, A1
Hayashi, M1
Mori, K2
Gotoh, T1
Yatome, C1
Pontisso, P1
Belluco, C1
Bertorelle, R1
De Moliner, L1
Chieco-Bianchi, L1
Nitti, D1
Lise, M1
Tudek, B1
Kowalczyk, P1
Cieśla, JM1
Yu, MW1
Cheng, SW1
Lin, MW1
Yang, SY1
Chang, HC1
Hsiao, TJ1
Lin, SM1
Lee, SD1
Chen, PJ1
Liu, CJ1
Chen, CJ1
Parsons, BL1
Culp, SJ1
Manjanatha, MG1
Heflich, RH1
Paik, WK1
Kim, S1
Ezirike, J1
Morris, HP2
Zylka, JM1
Plagemann, PG2
Bhargava, PM1
Szafarz, D1
Bornecque, CA1
Zajdela, F1
Graff, JC1
Tjernshaugen, H1
Gautvik, KM1
Rapaport, E1
Zamecnik, PC1
Yuki, H1
Kawasaki, H1
Imayuki, A1
Yajima, T1
Margison, GP1
Margison, JM1
O'Connor, TR1
Laval, J1
Zaima, M1
Noguchi, M1
Wada, Y1
Ozawa, K1
Haimanot, R1
Ueda, K1
Tsurimoto, T1
Nagahata, T1
Chisaka, O1
Matsubara, K1
Martin, DW1
Owen, NT1
Sugiura, K2
Brown, GB2
Ostroumova, MN1
Lamar, C1
Munger, WL1
Pitot, HC1
Gurd, JW1
Scholefield, PG1
Agostini, C1
Comi, P1
Mortara, G1
Shapot, VS1
Vornovitskaya, GI1
Gorozhanskaya, EG1
Davidova, SY1
Zhubanova, AA1
Krechetova, GD1
Chudinova, IA1
Reddy, R1
Ro-Choi, TS1
Henning, D1
Shibata, H1
Choi, YC1
Busch, H1
Criss, WE1
Poirier, LA1
Croce, CM1
Bakay, B1
Nyhan, WL1
Koprowski, H1
Nau, F1
Ho, Y1
Lin, HJ1
Dybing, E2
Kizer, DE1
Clouse, JA1
Teller, MN1
Parham, JC1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Real World Study on the Effect of HBV-DNA High-precision Detection Based Anti-viral Regimen Adjustment on Achieving Complete Virologic Response in Patients With Chronic Hepatitis B.(REACH)[NCT04724785]10,000 participants (Anticipated)Observational2020-12-01Recruiting
HBV Viral Suppression by Entecavir in Adefovir Partial Responders[NCT00704106]60 participants (Actual)Observational2008-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

23 reviews available for adenine and Cancer of Liver

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Hepatitis Delta: Prevalence, Natural History, and Treatment Options.
    Gastroenterology clinics of North America, 2020, Volume: 49, Issue:2

    Topics: Adenine; Antibodies, Viral; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Global Health;

2020
Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Disease markers, 2017, Volume: 2017

    Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Guanine; Hepatitis B v

2017
Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.
    Alimentary pharmacology & therapeutics, 2013, Volume: 38, Issue:2

    Topics: Adenine; Administration, Oral; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; He

2013
Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible?
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1

    Topics: Adenine; Administration, Oral; Antiviral Agents; Carcinoma, Hepatocellular; Fibrosis; Guanine; Hepat

2014
Impact of HBV therapy on the incidence of hepatocellular carcinoma.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Guanine; Hepatitis

2014
Managing hepatitis B to prevent liver cancer: recent advances.
    Expert review of gastroenterology & hepatology, 2014, Volume: 8, Issue:4

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans; Liver N

2014
Management of chronic hepatitis B in children: an unresolved issue.
    Journal of gastroenterology and hepatology, 2014, Volume: 29, Issue:5

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Carrier State; Child; Databases, Bibliographic

2014
Monotherapy for hepatitis B infection: a review of treatment options.
    Expert review of anti-infective therapy, 2015, Volume: 13, Issue:12

    Topics: Adenine; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Guanine; Hepatitis B, Chronic; Humans

2015
[Hepatitis B Virus Infection: Current Trends and Issues].
    Rinsho byori. The Japanese journal of clinical pathology, 2015, Volume: 63, Issue:6

    Topics: Adenine; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chron

2015
Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success.
    Best practice & research. Clinical gastroenterology, 2008, Volume: 22, Issue:6

    Topics: Adenine; Adenine Nucleotides; Alanine Transaminase; Carcinoma, Hepatocellular; DNA, Viral; Drug Admi

2008
[Chronic hepatitis B: current therapy].
    Bulletin de l'Academie nationale de medecine, 2008, Volume: 192, Issue:8

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Guanine; Hepatitis B Vacc

2008
Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2011, Volume: 43, Issue:4

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Hepatitis B, Chronic; Human

2011
[Prevention for the development of hepatitis B virus-related hepatocellular carcinoma by anti-viral treatment].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 4

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Interferons; Lam

2011
Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma.
    The Cochrane database of systematic reviews, 2011, Dec-07, Issue:12

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis B, Chroni

2011
Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients.
    Antiviral therapy, 2013, Volume: 18, Issue:7

    Topics: Adenine; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Disease Progression; Drug Resist

2013
Management of chronic hepatitis B virus infection in remote-dwelling Aboriginals and Torres Strait Islanders: an update for primary healthcare providers.
    The Medical journal of Australia, 2003, Jan-20, Volume: 178, Issue:2

    Topics: Adenine; Adolescent; Adult; Algorithms; Antiviral Agents; Australia; Carcinoma, Hepatocellular; Chil

2003
Management of patients with decompensated HBV cirrhosis.
    Seminars in liver disease, 2003, Volume: 23, Issue:1

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance; Hepatiti

2003
[New approaches in the treatment of hepatitis B].
    Deutsche medizinische Wochenschrift (1946), 2004, May-21, Volume: 129, Issue:21

    Topics: 2-Aminopurine; Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Contrai

2004
Management of chronic hepatitis B virus infection: current perspectives for the nurse practitioner.
    Journal of the American Academy of Nurse Practitioners, 2006, Volume: 18, Issue:5

    Topics: Acute Disease; Adenine; Algorithms; Antiviral Agents; Carcinoma, Hepatocellular; Carrier State; Dise

2006
Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression?
    The Netherlands journal of medicine, 2006, Volume: 64, Issue:6

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Fibrosis; Genotype; Hepatitis B e Antigens; He

2006
The metabolic activation and nucleic acid adducts of naturally-occurring carcinogens: recent results with ethyl carbamate and the spice flavors safrole and estragole.
    British journal of cancer, 1983, Volume: 48, Issue:1

    Topics: Adenine; Allylbenzene Derivatives; Animals; Anisoles; Biotransformation; Carcinogens, Environmental;

1983
Notes on some peculiarities of enzymic processes in malignant tumours and tissues of the host.
    Neoplasma, 1972, Volume: 19, Issue:4

    Topics: Adenine; Animals; Carbon Isotopes; Carcinoma, Hepatocellular; Catalase; Cholesterol; DNA, Neoplasm;

1972

Trials

6 trials available for adenine and Cancer of Liver

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial.
    Annals of surgery, 2015, Volume: 261, Issue:1

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis

2015
[A randomized controlled trial on 240-week monotherapy with entecavir or adefovir in patients with chronic hepatitis B and cirrhosis].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2015, Volume: 23, Issue:10

    Topics: Adenine; Aged; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Aspartate Aminotransferas

2015
Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.
    Hepatology (Baltimore, Md.), 2002, Volume: 36, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Base Sequence; Carcinoma, Hepatocellular; Conserved Sequence; DNA-

2002
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
    Gastroenterology, 2006, Volume: 131, Issue:6

    Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral;

2006
Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
    Gastroenterology, 2008, Volume: 134, Issue:7

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Circular; DNA, V

2008

Other Studies

131 other studies available for adenine and Cancer of Liver

ArticleYear
Reactive Oxygen Species Mediate 6c-Induced Mitochondrial and Lysosomal Dysfunction, Autophagic Cell Death, and DNA Damage in Hepatocellular Carcinoma.
    International journal of molecular sciences, 2021, Oct-12, Volume: 22, Issue:20

    Topics: Acetylcysteine; Adenine; Antioxidants; Autophagic Cell Death; Autophagosomes; Carcinoma, Hepatocellu

2021
DNA N6-Adenine methylation in HBV-related hepatocellular carcinoma.
    Gene, 2022, May-15, Volume: 822

    Topics: Adenine; Carcinoma, Hepatocellular; DNA Methylation; Epigenesis, Genetic; Genome-Wide Association St

2022
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B.
    Liver international : official journal of the International Association for the Study of the Liver, 2022, Volume: 42, Issue:7

    Topics: Adenine; Alanine; Carcinoma, Hepatocellular; Female; Hepatitis B, Chronic; Humans; Liver Neoplasms;

2022
Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis.
    BMC infectious diseases, 2022, Jul-14, Volume: 22, Issue:1

    Topics: Adenine; Alanine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Hepatitis B virus; Hepati

2022
Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir.
    The Tohoku journal of experimental medicine, 2022, Nov-12, Volume: 258, Issue:4

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Fumarates; Hepatitis B, Chronic; H

2022
The expression of interleukin-1β in patients with chronic hepatitis B treated with pegylated-interferon-alpha combined with tenofovir disoproxil fumarate and monotherapy.
    BMC gastroenterology, 2023, May-19, Volume: 23, Issue:1

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; DNA, Viral; Drug Therapy, Comb

2023
Induction of Autophagic Death of Human Hepatocellular Carcinoma Cells by Armillaridin from
    The American journal of Chinese medicine, 2019, Volume: 47, Issue:6

    Topics: Adenine; Antineoplastic Agents, Phytogenic; Armillaria; Autophagic Cell Death; Carcinoma, Hepatocell

2019
Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma.
    Molecular cancer therapeutics, 2020, Volume: 19, Issue:2

    Topics: Adenine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

2020
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog.
    Journal of gastroenterology and hepatology, 2020, Volume: 35, Issue:9

    Topics: Adenine; Adult; Alanine; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Cohort Studies;

2020
Arctigenin suppresses cell proliferation via autophagy inhibition in hepatocellular carcinoma cells.
    Journal of natural medicines, 2020, Volume: 74, Issue:3

    Topics: Adenine; Apoptosis; Apoptosis Regulatory Proteins; Arctium; Autophagy; Carcinoma, Hepatocellular; Ce

2020
Combination of HSP90 and autophagy inhibitors promotes hepatocellular carcinoma apoptosis following incomplete thermal ablation.
    Molecular medicine reports, 2020, Volume: 22, Issue:1

    Topics: Adenine; Animals; Apoptosis; Autophagy; Benzoquinones; Carcinoma, Hepatocellular; Cell Line, Tumor;

2020
Effect of Oleanolic Acid on Apoptosis and Autophagy of SMMC-7721 Hepatoma Cells.
    Medical science monitor : international medical journal of experimental and clinical research, 2020, May-19, Volume: 26

    Topics: Adenine; Adenosine Triphosphate; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor;

2020
Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Digestive diseases and sciences, 2021, Volume: 66, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B, Chronic;

2021
The significance of m6A RNA methylation regulators in predicting the prognosis and clinical course of HBV-related hepatocellular carcinoma.
    Molecular medicine (Cambridge, Mass.), 2020, 06-17, Volume: 26, Issue:1

    Topics: Adenine; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Gene Express

2020
Circ-SPECC1 modulates TGFβ2 and autophagy under oxidative stress by sponging miR-33a to promote hepatocellular carcinoma tumorigenesis.
    Cancer medicine, 2020, Volume: 9, Issue:16

    Topics: Adenine; Animals; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, T

2020
Puerarin 6″-O-xyloside suppressed HCC via regulating proliferation, stemness, and apoptosis with inhibited PI3K/AKT/mTOR.
    Cancer medicine, 2020, Volume: 9, Issue:17

    Topics: AC133 Antigen; Adenine; Animals; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor;

2020
Enhanced targeted delivery of adenine to hepatocellular carcinoma using glycyrrhetinic acid-functionalized nanoparticles in vivo and in vitro.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 131

    Topics: Adenine; Animals; Anti-Inflammatory Agents; Carcinoma, Hepatocellular; Drug Delivery Systems; Female

2020
Development and validation of a m
    Biomarkers in medicine, 2020, Volume: 14, Issue:13

    Topics: Adenine; Aged; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cohort Studies; DNA Methylation; Female

2020
HCC risk reduction with oral nucleos(t)ide analogues in patients with chronic hepatitis B: Not perfect, not good enough.
    Journal of gastroenterology and hepatology, 2020, Volume: 35, Issue:10

    Topics: Adenine; Administration, Oral; Alanine; Carcinoma, Hepatocellular; DNA, Viral; Guanine; Hepatitis B

2020
3-Methyladenine-enhanced susceptibility to sorafenib in hepatocellular carcinoma cells by inhibiting autophagy.
    Anti-cancer drugs, 2021, 04-01, Volume: 32, Issue:4

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Hepatocell

2021
METTL3/IGF2BP1/CD47 contributes to the sublethal heat treatment induced mesenchymal transition in HCC.
    Biochemical and biophysical research communications, 2021, 03-26, Volume: 546

    Topics: Adenine; Carcinoma, Hepatocellular; CD47 Antigen; Cell Line, Tumor; Cell Movement; Epithelial-Mesenc

2021
MiR-513b-5p represses autophagy during the malignant progression of hepatocellular carcinoma by targeting PIK3R3.
    Aging, 2021, 06-13, Volume: 13, Issue:12

    Topics: Adenine; Apoptosis; Autophagy; Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Move

2021
TGF-β1 promotes human hepatic carcinoma HepG2 cells invasion by upregulating autophagy.
    European review for medical and pharmacological sciences, 2017, Volume: 21, Issue:11

    Topics: Adenine; Autophagy; Beclin-1; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Hep G2 Ce

2017
Adefovir-Induced Hypophosphatemic Osteomalacia Mimicking Bone Metastases From Primary Hepatocarcinoma.
    Clinical nuclear medicine, 2017, Volume: 42, Issue:9

    Topics: Adenine; Bone Neoplasms; Humans; Hypophosphatemia; Liver Neoplasms; Male; Middle Aged; Organophospho

2017
HSF1 upregulates ATG4B expression and enhances epirubicin-induced protective autophagy in hepatocellular carcinoma cells.
    Cancer letters, 2017, 11-28, Volume: 409

    Topics: Adenine; Animals; Antibiotics, Antineoplastic; Autophagy; Autophagy-Related Proteins; Carcinoma, Hep

2017
Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
    Medicine, 2017, Volume: 96, Issue:44

    Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Hepatitis B

2017
Inhibition of autophagy in hepatocarcinoma cells promotes chemotherapeutic agent-induced apoptosis during nutrient deprivation.
    Oncology reports, 2018, Volume: 39, Issue:2

    Topics: Adenine; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Carcinoma, Hepat

2018
Subacute Invasive Aspergillosis Associated With Sorafenib Therapy for Hepatocellular Carcinoma.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 06-18, Volume: 67, Issue:1

    Topics: Adenine; Aspergillosis; Carcinoma, Hepatocellular; Humans; Invasive Fungal Infections; Liver Neoplas

2018
Juglone induces apoptosis and autophagy via modulation of mitogen-activated protein kinase pathways in human hepatocellular carcinoma cells.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2018, Volume: 116, Issue:Pt B

    Topics: Acetylcysteine; Adenine; Amino Acid Chloromethyl Ketones; Androstadienes; Apoptosis; Autophagy; Carc

2018
The biological role of autophagy in regulating and controlling the proliferation of liver cancer cells induced by bufalin.
    Oncology reports, 2018, Volume: 39, Issue:6

    Topics: Adenine; Autophagy; Beclin-1; Bufanolides; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor;

2018
Resveratrol inhibited the progression of human hepatocellular carcinoma by inducing autophagy via regulating p53 and the phosphoinositide 3‑kinase/protein kinase B pathway.
    Oncology reports, 2018, Volume: 40, Issue:5

    Topics: Adenine; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Benzothiazoles; Carcinoma, Hepatoc

2018
The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection.
    Medicine, 2019, Volume: 98, Issue:6

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Hepatitis B e Antigens; He

2019
Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2019, Volume: 29, Issue:4

    Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; China; Female; Guanine; Hepatitis

2019
[Adefovir Dipivoxil-induced Fanconi's Syndrome and Osteomalacia Following Multiple Bone Fractures in a Patient with Chronic Hepatitis B].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2019, Volume: 139, Issue:4

    Topics: Adenine; Aged; Carcinoma, Hepatocellular; Fanconi Syndrome; Fractures, Bone; Hepatitis B, Chronic; H

2019
A simple and low-cost screen printed electrode for hepatocellular carcinoma methylation detection.
    The Analyst, 2019, May-13, Volume: 144, Issue:10

    Topics: Adenine; Adsorption; Carbon; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA; DNA Methylation; Elec

2019
Recombinant human arginase I elicited immunosuppression in activated macrophages through inhibiting autophagy.
    Applied microbiology and biotechnology, 2019, Volume: 103, Issue:12

    Topics: Adenine; Animals; Arginase; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferati

2019
Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model.
    European journal of gastroenterology & hepatology, 2019, Volume: 31, Issue:11

    Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B Surf

2019
Hepatitis B therapy, hepatocellular carcinoma and HBsAg mutants.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Volume: 45, Issue:6

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy, Combination; Hepatit

2013
Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Antiviral therapy, 2013, Volume: 18, Issue:4

    Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Administrat

2013
Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
    International journal of molecular medicine, 2013, Volume: 31, Issue:6

    Topics: Adenine; Apoptosis; Autophagy; Autophagy-Related Protein 5; Carcinoma, Hepatocellular; Cell Line, Tu

2013
Tumor necrosis factor-α attenuates starvation-induced apoptosis through upregulation of ferritin heavy chain in hepatocellular carcinoma cells.
    BMC cancer, 2013, Sep-25, Volume: 13

    Topics: Adenine; Apoferritins; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Enzyme Activation; Ge

2013
Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients.
    Clinical and molecular hepatology, 2013, Volume: 19, Issue:3

    Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Administration Schedul

2013
AZD8055 induces cell death associated with autophagy and activation of AMPK in hepatocellular carcinoma.
    Oncology reports, 2014, Volume: 31, Issue:2

    Topics: Adenine; AMP-Activated Protein Kinases; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autopha

2014
The c10orf10 gene product is a new link between oxidative stress and autophagy.
    Biochimica et biophysica acta, 2014, Volume: 1843, Issue:6

    Topics: Adenine; Animals; Autophagy; Biomarkers; Blotting, Western; Carcinoma, Hepatocellular; Chlorocebus a

2014
[Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline].
    Orvosi hetilap, 2014, Volume: 155 Suppl

    Topics: Adenine; Antiviral Agents; Consensus; Drug Administration Schedule; Drug Therapy, Combination; Evide

2014
Association study of c.910A>G and c.1686C>G polymorphisms in XRCC1 gene with risk of hepatocellular carcinoma in the Chinese population.
    Genetics and molecular research : GMR, 2014, Feb-28, Volume: 13, Issue:1

    Topics: Adenine; Aged; Asian People; Carcinoma, Hepatocellular; Case-Control Studies; Cytosine; DNA-Binding

2014
Antiviral therapy of chronic hepatitis B.
    Intervirology, 2014, Volume: 57, Issue:3-4

    Topics: Adenine; Antiviral Agents; Arabinofuranosyluracil; Carcinoma, Hepatocellular; Gene Products, pol; Gu

2014
Carnosic acid induces autophagic cell death through inhibition of the Akt/mTOR pathway in human hepatoma cells.
    Journal of applied toxicology : JAT, 2015, Volume: 35, Issue:5

    Topics: Abietanes; Adenine; Apoptosis; Autophagy; Cell Proliferation; Chloroquine; Gene Silencing; Hep G2 Ce

2015
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.
    Journal of hepatology, 2015, Volume: 62, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Greece; Guan

2015
The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
    Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:11-12

    Topics: Adenine; Adult; Antiviral Agents; Canada; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B e

2014
NS5ATP9 Promotes Beclin 1-Dependent Starvation-Induced Autophagy of Hepatoblastoma Cells.
    Journal of cellular biochemistry, 2015, Volume: 116, Issue:8

    Topics: Adenine; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Carrier Proteins; Cell Proliferation; C

2015
MRI visible drug eluting magnetic microspheres for transcatheter intra-arterial delivery to liver tumors.
    Theranostics, 2015, Volume: 5, Issue:5

    Topics: Adenine; Alginates; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Carriers; Glucuroni

2015
Long-term follow-up of HBsAg-positive patients in Germany.
    European journal of gastroenterology & hepatology, 2016, Volume: 28, Issue:1

    Topics: Adenine; Adult; Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Therapy,

2016
Blocking autophagy enhances meloxicam lethality to hepatocellular carcinoma by promotion of endoplasmic reticulum stress.
    Cell proliferation, 2015, Volume: 48, Issue:6

    Topics: Adenine; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Relat

2015
Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma.
    Oncotarget, 2016, May-10, Volume: 7, Issue:19

    Topics: Adenine; Administration, Oral; Adolescent; Adult; Amino Acid Sequence; Antiviral Agents; Biopsy; Car

2016
Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:2

    Topics: Adenine; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Carcinoma,

2017
The decreased N
    Biochemical and biophysical research communications, 2016, Nov-04, Volume: 480, Issue:1

    Topics: 3T3-L1 Cells; 5-Methylcytosine; Adenine; Animals; Chromatography, High Pressure Liquid; DNA; Gene Ex

2016
P300/CBP-associated factor (PCAF) inhibits the growth of hepatocellular carcinoma by promoting cell autophagy.
    Cell death & disease, 2016, 10-06, Volume: 7, Issue:10

    Topics: Adenine; Animals; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferat

2016
AKT/mTOR signaling pathway is involved in salvianolic acid B-induced autophagy and apoptosis in hepatocellular carcinoma cells.
    International journal of oncology, 2016, Volume: 49, Issue:6

    Topics: Adenine; Antineoplastic Agents; Apoptosis; Autophagy; Beclin-1; Benzofurans; Carcinoma, Hepatocellul

2016
Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.
    Gut, 2018, Volume: 67, Issue:2

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asymptomatic Infections; Carcinoma, Hepat

2018
Cancer-associated Fibroblasts Promote Irradiated Cancer Cell Recovery Through Autophagy.
    EBioMedicine, 2017, Volume: 17

    Topics: 3-Hydroxybutyric Acid; Adenine; Aged; Aged, 80 and over; Animals; Autophagy; Cell Line, Tumor; Cells

2017
OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma.
    Cancer research, 2008, Nov-15, Volume: 68, Issue:22

    Topics: 3-Phosphoinositide-Dependent Protein Kinases; Adenine; Animals; Apoptosis; Autophagy; Autophagy-Rela

2008
Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil.
    Intervirology, 2008, Volume: 51, Issue:6

    Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Drug Resistance, Vira

2008
Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma?
    Antiviral therapy, 2009, Volume: 14, Issue:2

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Viral; H

2009
[Therapy of chronic hepatitis B. Tenofovir--first choice in current EASL guidelines].
    MMW Fortschritte der Medizin, 2009, May-28, Volume: 151, Issue:22

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Drug Resistance, Viral; Evidence-Based Medicin

2009
Interaction between cytochrome P450 1A2 genetic polymorphism and cigarette smoking on the risk of hepatocellular carcinoma in a Japanese population.
    Carcinogenesis, 2009, Volume: 30, Issue:10

    Topics: Adenine; Adult; Age Distribution; Aged; Carcinoma, Hepatocellular; Cytochrome P-450 CYP1A1; Cytochro

2009
Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance.
    European journal of internal medicine, 2009, Volume: 20, Issue:5

    Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Resistance,

2009
Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells.
    Autophagy, 2009, Volume: 5, Issue:8

    Topics: Adenine; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Carcinoma, Hepatocellular; C

2009
Abrogation of glucocorticoid receptor dimerization correlates with dissociated glucocorticoid behavior of compound a.
    The Journal of biological chemistry, 2010, Mar-12, Volume: 285, Issue:11

    Topics: Adenine; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Chlorocebus aethiops; Citrates; COS C

2010
A novel sesquiterpene Hirsutanol A induces autophagical cell death in human hepatocellular carcinoma cells by increasing reactive oxygen species.
    Chinese journal of cancer, 2010, Volume: 29, Issue:7

    Topics: Acetylcysteine; Adenine; Agaricales; Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Ce

2010
HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy.
    Liver international : official journal of the International Association for the Study of the Liver, 2010, Volume: 30, Issue:10

    Topics: Adenine; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Catheter Ablation; Disease-Free S

2010
Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma.
    Autophagy, 2010, Volume: 6, Issue:8

    Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Line,

2010
[Treatment has a positive impact on the long-term evolution of chronic hepatitis B].
    Gastroenterologie clinique et biologique, 2010, Volume: 34 Suppl 2

    Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Guanine; Hepatitis B

2010
Autophagy inhibition enhances etoposide-induced cell death in human hepatoma G2 cells.
    International journal of molecular medicine, 2011, Volume: 27, Issue:4

    Topics: Adenine; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autoph

2011
Sensitizing effect of 3-methyladenine on radiation-induced cytotoxicity in radio-resistant HepG2 cells in vitro and in tumor xenografts.
    Chemico-biological interactions, 2011, Jul-15, Volume: 192, Issue:3

    Topics: Adenine; Animals; Apoptosis; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Radiatio

2011
Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues.
    Journal of vascular and interventional radiology : JVIR, 2012, Volume: 23, Issue:3

    Topics: Adenine; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolizat

2012
Targeting autophagy potentiates chemotherapy-induced apoptosis and proliferation inhibition in hepatocarcinoma cells.
    Cancer letters, 2012, Jul-28, Volume: 320, Issue:2

    Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin

2012
BND-12, a novel nonhaematotoxic naphthalimide derivative, inhibits tumour growth and metastasis of hepatocellular carcinoma.
    The Journal of pharmacy and pharmacology, 2012, Volume: 64, Issue:10

    Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cel

2012
Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis.
    Journal of hepatology, 2013, Volume: 58, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Child; Ch

2013
Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load.
    Annals of surgical oncology, 2013, Volume: 20, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease-Free Survival; DNA, Viral; Fema

2013
Restoration of klotho expression induces apoptosis and autophagy in hepatocellular carcinoma cells.
    Cellular oncology (Dordrecht), 2013, Volume: 36, Issue:2

    Topics: Adenine; Amino Acid Chloromethyl Ketones; Apoptosis; Autophagy; Blotting, Western; Carcinoma, Hepato

2013
Prostaglandin E2 promotes liver cancer cell growth by the upregulation of FUSE-binding protein 1 expression.
    International journal of oncology, 2013, Volume: 42, Issue:3

    Topics: Abortifacient Agents, Nonsteroidal; Adenine; Adenylyl Cyclase Inhibitors; Carrier Proteins; Cell Lin

2013
Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro.
    Hepatology (Baltimore, Md.), 2003, Volume: 37, Issue:1

    Topics: Adenine; Baculoviridae; Carcinoma, Hepatocellular; Drug Resistance, Viral; Hepatitis B Core Antigens

2003
PHYSIOLOGICAL DISPOSITION AND THERAPEUTIC CONSEQUENCES OF ADENINE ADMINISTERED VIA THE GASTROINTESTINAL TRACT IN NORMAL AND TUMOR-BEARING MICE.
    Cancer research, 1963, Volume: 23

    Topics: Adenine; Adenine Nucleotides; Animals; Carbon Isotopes; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatoc

1963
THE EFFECT OF SOME TRANSPLANTABLE TUMORS ON THE NUCLEIC ACID METABOLISM OF THE HOST TISSUES.
    Canadian journal of biochemistry and physiology, 1963, Volume: 41

    Topics: Adenine; Animals; Carbon Isotopes; Carcinoma 256, Walker; Carcinoma, Ehrlich Tumor; Carcinoma, Hepat

1963
[ON THE EXISTENCE OF RAPIDLY LABELED DESOXYRIBONUCLEIC FRACTION IN ANIMAL CELLS].
    Comptes rendus hebdomadaires des seances de l'Academie des sciences, 1964, Feb-10, Volume: 258

    Topics: Adenine; Animals; Carbon Isotopes; Carcinoma, Hepatocellular; DNA; Liver; Liver Neoplasms; Neoplasm

1964
CONCENTRATIONS AND RATES OF SYNTHESIS OF NICOTINAMIDE-ADENINE-DINUCLEODIDE PHOSPHATE IN PRECANCEROUS LIVERS AND HEPATOMAS INDUCED BY AZO-DYE FEEDING.
    Nature, 1964, Mar-14, Volume: 201

    Topics: Adenine; Carcinogens; Carcinoma, Hepatocellular; Liver; Liver Neoplasms; NADP; Neoplasms; Neoplasms,

1964
THE EFFECT OF ACTINOMYCIN D ON THE INCORPORATION OF C14-FORMATE INTO NUCLEIC ACIDS OF EHRLICH ASCITES CARCINOMA AND NOVIKOFF HEPATOMA IN VITRO.
    Canadian journal of biochemistry, 1964, Volume: 42

    Topics: Adenine; Animals; Ascites; Carbon Isotopes; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Dac

1964
RIBONUCLEIC ACID SYNTHESIS AND TURNOVER IN RAT LIVER AND IN A RAPIDLY GROWING TRANSPLANTABLE HEPATOMA.
    Biochimica et biophysica acta, 1964, Jul-22, Volume: 87

    Topics: Adenine; Carcinoma, Hepatocellular; Cytosine; Electrophoresis; Guanine; Histocytochemistry; Liver; L

1964
Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine.
    Hepatology (Baltimore, Md.), 2005, Volume: 42, Issue:1

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepatitis B e

2005
In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:3

    Topics: Adenine; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Dideoxynucleosides;

2006
Decompensated lamivudine-resistant hepatitis B virus-related cirrhosis treated successfully with adefovir dipivoxil allowing surgery for hepatocellular carcinoma.
    Internal medicine (Tokyo, Japan), 2007, Volume: 46, Issue:7

    Topics: Adenine; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Disease Progression; Drug Resis

2007
Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture.
    Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:9

    Topics: Adenine; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Cytosine; Ducks; Hepatitis B virus; H

1994
p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers.
    Carcinogenesis, 1994, Volume: 15, Issue:1

    Topics: Adenine; Aged; Base Composition; Base Sequence; Carcinoma, Hepatocellular; DNA; Exons; Gene Amplific

1994
Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type.
    Cancer, 1993, Jun-15, Volume: 71, Issue:12

    Topics: Adenine; Adenocarcinoma; Aspartic Acid; Biology; Codon; Colonic Neoplasms; Gene Frequency; Genes, ra

1993
Mutagenic DNA base modifications are correlated with lesions in nonneoplastic hepatic tissue of the English sole carcinogenesis model.
    Cancer research, 1996, Dec-15, Volume: 56, Issue:24

    Topics: Adenine; Age Factors; Animals; Confounding Factors, Epidemiologic; Fish Diseases; Guanine; Liver Dis

1996
Hepatocellular carcinoma in patients from northern Sweden with acute intermittent porphyria: morphology and mutations.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 1996, Volume: 5, Issue:5

    Topics: Adenine; Aged; Aged, 80 and over; Alleles; Base Sequence; Carcinoma, Hepatocellular; Cell Division;

1996
Effects of a frequent double-nucleotide basal core promoter mutation and its putative single-nucleotide precursor mutations on hepatitis B virus gene expression and replication.
    The Journal of general virology, 1997, Volume: 78 ( Pt 8)

    Topics: Adenine; Base Sequence; Biological Factors; Carcinoma, Hepatocellular; Gene Expression Regulation, V

1997
Synthesis of DHPA analogs and their inhibitory activities of human recombinant S-adenosyl-L-homocysteine hydrolase.
    Nucleic acids symposium series, 1997, Issue:37

    Topics: Adenine; Adenosylhomocysteinase; Antiviral Agents; Carcinoma, Hepatocellular; Drug Design; Enzyme In

1997
Hepatitis C virus infection associated with human hepatocellular carcinoma: lack of correlation with p53 abnormalities in Caucasian patients.
    Cancer, 1998, Oct-15, Volume: 83, Issue:8

    Topics: Adenine; Aged; Carcinoma, Hepatocellular; Codon; Cohort Studies; DNA, Viral; Exons; Female; Genes, p

1998
Localization of chloroacetaldehyde-induced DNA damage in human p53 gene by DNA polymerase fingerprint analysis.
    IARC scientific publications, 1999, Issue:150

    Topics: Acetaldehyde; Adenine; Animals; Cytosine; DNA Damage; DNA Fingerprinting; DNA Repair; Exons; Genes,

1999
Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma.
    Journal of the National Cancer Institute, 2000, Dec-20, Volume: 92, Issue:24

    Topics: Adenine; Adult; Aged; Carcinoma, Hepatocellular; Case-Control Studies; Cohort Studies; Cytosine; Gua

2000
Occurrence of H-ras codon 61 CAA to AAA mutation during mouse liver tumor progression.
    Carcinogenesis, 2002, Volume: 23, Issue:6

    Topics: Adenine; Animals; Benzo(a)pyrene; Carcinogens; Coal Tar; Codon; Cytosine; Disease Progression; Genes

2002
S-adenosylmethionine:protein methyltransferases in hepatomas.
    Cancer research, 1975, Volume: 35, Issue:5

    Topics: Adenine; Animals; Arginine; Carcinoma, Hepatocellular; Cell Nucleus; Cytosol; Histones; Liver; Liver

1975
Purine and pyrimidine transport by cultured Novikoff cells. Specificities and mechanism of transport and relationship to phosphoribosylation.
    The Journal of biological chemistry, 1975, Aug-10, Volume: 250, Issue:15

    Topics: Adenine; Animals; Biological Transport, Active; Calorimetry; Carcinoma, Hepatocellular; Cell Line; C

1975
Uptake in vitro of nucleic acid precursors and nucleic acids by Zajdela ascitic hepatoma cells.
    The Journal of membrane biology, 1975, Jul-24, Volume: 22, Issue:3-4

    Topics: Adenine; Animals; Biological Transport, Active; Carcinoma, Hepatocellular; Cell Line; DNA; DNA, Bact

1975
Alanosine toxicity in Novikoff rat hepatoma cells due to inhibition of the conversion of inosine monophosphate to adenosine monophosphate.
    Cancer research, 1976, Volume: 36, Issue:4

    Topics: Adenine; Adenosine Monophosphate; Adenosine Triphosphate; Alanine; Aspartic Acid; Carcinoma, Hepatoc

1976
Nucleotidase activity in regenerating liver and in clonal strains of hepatoma and pituitary cells in culture.
    Journal of cellular physiology, 1976, Volume: 88, Issue:1

    Topics: Adenine; Animals; Carcinoma, Hepatocellular; Cell Division; Clone Cells; DNA; Liver; Liver Neoplasms

1976
Incorporation of adenosine into ATP: formation of compartmentalized ATP.
    Proceedings of the National Academy of Sciences of the United States of America, 1976, Volume: 73, Issue:9

    Topics: Adenine; Adenosine; Adenosine Diphosphate; Adenosine Triphosphate; Animals; Carcinoma, Hepatocellula

1976
Determination of 6-methyladenine in DNA by high-performance liquid chromatography.
    Journal of chromatography, 1979, Jan-21, Volume: 168, Issue:2

    Topics: Adenine; Animals; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Cattle; Chemical Phenomena; C

1979
Methylated purines in the deoxyribonucleic acid of various Syrian-golden-hamster tissues after administration of a hepatocarcinogenic dose of dimethylnitrosamine.
    The Biochemical journal, 1976, Sep-01, Volume: 157, Issue:3

    Topics: Adenine; Animals; Cricetinae; Dimethylnitrosamine; DNA; Guanine; Kidney; Liver; Liver Neoplasms; Lun

1976
Human cDNA expressing a functional DNA glycosylase excising 3-methyladenine and 7-methylguanine.
    Biochemical and biophysical research communications, 1991, May-15, Volume: 176, Issue:3

    Topics: Adenine; Amino Acid Sequence; Animals; Base Sequence; Carcinoma, Hepatocellular; Cell Line; Cloning,

1991
Sequential decrease in platelet energy charge after hepatic resection in cirrhotics.
    American journal of surgery, 1990, Volume: 159, Issue:2

    Topics: Adenine; Adenosine Triphosphate; Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blood Platelet

1990
4,6-Diamino-5-formamidopyrimidine, 8-hydroxyguanine and 8-hydroxyadenine in DNA from neoplastic liver of English sole exposed to carcinogens.
    Biochemical and biophysical research communications, 1990, Dec-14, Volume: 173, Issue:2

    Topics: Adenine; Animals; Carcinogens; DNA, Neoplasm; Flatfishes; Free Radicals; Hydroxides; Hydroxyl Radica

1990
An in vitro system for screening anti-hepatitis B virus drugs.
    Virology, 1989, Volume: 169, Issue:1

    Topics: Acyclovir; Adenine; Antiviral Agents; Blotting, Southern; Carcinoma, Hepatocellular; Cytarabine; Did

1989
Repression and derepression of purine biosynthesis in mammalian hepatoma cells in culture.
    The Journal of biological chemistry, 1972, Sep-10, Volume: 247, Issue:17

    Topics: Acyltransferases; Adenine; Animals; Azacitidine; Carbon Isotopes; Carcinoma, Hepatocellular; Clone C

1972
Purine N-oxides. XIX. On the oncogenic N-oxide derivatives of guanine and xanthine and a nononcogenic isomer of xanthine N-oxide.
    Cancer research, 1967, Volume: 27, Issue:5

    Topics: Adenine; Animals; Carcinoma, Hepatocellular; Guanine; Liver Neoplasms; Mercaptopurine; Neoplasms; Ne

1967
[Purine synthesis in the mouse hepatoma and liver tissue].
    Voprosy onkologii, 1966, Volume: 12, Issue:1

    Topics: Adenine; Adenine Nucleotides; Animals; Carbon Isotopes; Carcinoma, Hepatocellular; Formates; Guanine

1966
Studies on a 32S component of nuclear RNA.
    Archives of biochemistry and biophysics, 1967, Volume: 119, Issue:1

    Topics: Adenine; Animals; Carcinoma, Hepatocellular; Cell Nucleus; Centrifugation, Zonal; Chromatography, Ge

1967
The energy metabolism of Novikoff ascites hepatoma cells. I. The effects of glucose on the intracellular level of adenine nucleotides.
    Canadian journal of biochemistry, 1971, Volume: 49, Issue:6

    Topics: Adenine; Adenine Nucleotides; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate

1971
Action of ethionine, methionine, ATP, adenine, albumin and Ca 2+ on protein synthesis of normal and tumor cells.
    Experimental and molecular pathology, 1972, Volume: 16, Issue:3

    Topics: Adenine; Adenosine Triphosphate; Albumins; Amino Acids; Analysis of Variance; Animals; Calcium; Carb

1972
MOdified nucleosides of nuclear and nucleolar low molecular weight ribonucleic acid.
    The Journal of biological chemistry, 1972, Nov-25, Volume: 247, Issue:22

    Topics: Adenine; Animals; Carcinoma, Hepatocellular; Cell Nucleolus; Cell Nucleus; Chromatography, Gel; Chro

1972
Influence of hormones on the growth of hepatomas and induction of adenylate and pyruvate kinases.
    Cancer research, 1973, Volume: 33, Issue:5

    Topics: Adenine; Adrenal Glands; Adrenalectomy; Animals; Carcinoma, Hepatocellular; Dactinomycin; Diabetes M

1973
Folate deficiency in rats bearing the Walker tumor 256 and the Novikoff hepatoma.
    Cancer research, 1973, Volume: 33, Issue:9

    Topics: Adenine; Animals; Carcinoma 256, Walker; Carcinoma, Hepatocellular; Choline; Diet; FIGLU Test; Folic

1973
Reexpression of the rat hypoxanthine phosphoribosyltransferase gene in rat-human hybrids.
    Proceedings of the National Academy of Sciences of the United States of America, 1973, Volume: 70, Issue:9

    Topics: Adenine; Animals; Carcinoma, Hepatocellular; Cell Fusion; Clone Cells; Electrophoresis, Polyacrylami

1973
Differences in in vivo methylation patterns of tyrosine and histidine transfer ribonucleic acids from rat liver and Novikoff hepatoma.
    Biochemistry, 1974, Mar-12, Volume: 13, Issue:6

    Topics: Adenine; Amino Acyl-tRNA Synthetases; Animals; Carcinoma, Hepatocellular; Chromatography, DEAE-Cellu

1974
Patterns of excretion of methylated purines in hepatocellular carcinoma.
    Cancer research, 1974, Volume: 34, Issue:5

    Topics: Adenine; Adult; Carcinoma, Hepatocellular; Chromatography, Paper; Creatine; Guanine; Humans; Hydroly

1974
Cycloheximide inhibition of hypoxanthine transport cultured cells.
    Biochimica et biophysica acta, 1974, Nov-27, Volume: 373, Issue:1

    Topics: Adenine; Aminoisobutyric Acids; Animals; Biological Transport; Carbon Radioisotopes; Carcinoma, Hepa

1974
Acinomycin D and purine transport in cultured rat hepatoma cells.
    Biochemical pharmacology, 1974, Nov-01, Volume: 23, Issue:21

    Topics: Adenine; Animals; Biological Transport, Active; Carbon Radioisotopes; Carcinoma, Hepatocellular; Cel

1974
On relationships between induction of liver cancer with azo dyes and changes in nuclear RNA metabolism during carcinogenesis.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1969, Volume: 132, Issue:3

    Topics: Adenine; Animals; Azo Compounds; Carbon Isotopes; Cell Nucleus; Diet; Female; Liver; Liver Neoplasms

1969
A comparison of the oncogenicities of 3-hydroxyxanthine, guanine 3-N-oxide, and some related compounds.
    Cancer research, 1970, Volume: 30, Issue:1

    Topics: Adenine; Animals; Chemical Phenomena; Chemistry; Female; Granuloma; Guanine; Injections, Subcutaneou

1970